Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis

Martina B. Lorey 1,2, Katariina Öörni 1,2* and Petri T. Kovanen 1

1 Atherosclerosis Research Laboratory, Wihuri Research Institute, Helsinki, Finland, 2 Molecular and Integrative Biosciences, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland

Circulating apolipoprotein B-containing lipoproteins, notably the low-density lipoproteins, enter the inner layer of the arterial wall, the intima, where a fraction of them is retained and modified by proteases, lipases, and oxidizing agents and enzymes. The modified lipoproteins and various modification products, such as fatty acids, ceramides, lysophospholipids, and oxidized lipids induce inflammatory reactions in the macrophages and the covering endothelial cells, initiating an increased leukocyte diapedesis. Lipolysis of the lipoproteins also induces the formation of cholesterol crystals with strong proinflammatory properties. Modified and aggregated lipoproteins, cholesterol crystals, and lipoproteins isolated from human atherosclerotic lesions, all can activate macrophages and thereby induce the secretion of proinflammatory cytokines, chemokines, and enzymes. The extent of lipoprotein retention, modification, and aggregation have been shown to depend largely on differences in the composition of the circulating lipoprotein particles. These properties can be modified by pharmacological means, and thereby provide opportunities for clinical interventions regarding the prevention and treatment of atherosclerotic vascular diseases.

Keywords: modified lipoproteins, inflammation, atherogenesis, endothelial dysfunction, foam cell

INTRODUCTION

Atherosclerosis develops in the inner layer of the arterial wall, the intima. Atherosclerosis-prone locations, such as bifurcations of the coronary arteries, are characterized by a thick extracellular matrix containing collagen, elastin, and proteoglycans, and the presence of increased numbers of lipid-laden macrophages since childhood (1–3). Apolipoprotein B (apoB)-containing lipoproteins, i.e., LDL and remnant lipoproteins, such as small VLDL, IDL, and chylomicron remnants, cross the endothelial cell layer from the circulation into the intima (4), where they can become entrapped by the dense extracellular matrix (5–7).

A fraction of the lipoproteins can be modified in the intima by oxidizing agents and enzymes, proteases, and lipases secreted by local cells (5, 6). Such modifications of the lipoprotein structure have been shown to induce aggregation and fusion of lipoprotein particles (8, 9). Atherosclerotic lesions contain lipoproteins that show signs of extensive oxidation, proteolysis, and lipolysis of the various lipid molecules and that are often aggregated [recently reviewed in (10)]. The modified lipoproteins can be taken up by macrophages, which are converted into foam cells. The initial lesions of atherosclerosis, the fatty streaks, are characterized by the presence of numerous foam cells and can appear at any age, independent of risk factors for atherosclerotic cardiovascular
Atherosclerotic lesions contain both neutral and acidic proteases and lipases that can modify lipoprotein particles. Among the proteases are serine proteases, cathepsins, and metalloproteinases that have been shown to degrade apoB-100 (23–26). Of note, these proteases may also degrade the structural proteins like collagens in the extracellular matrix and may thus lead to cap-thinning of the plaques [reviewed in (27)]. The extent of proteolytic degradation of the protein components of the lipoproteins depends on the protease: plasmin, for example, can induce fragmentation of apoB-100 of LDL and does not induce LDL aggregation and fusion, while cathepsins proteolyze apoB-100 of LDL into small fragments and induce the generation of large, fused particles (24, 28, 29). Proteolysis can also promote lipolytic modifications of the lipoproteins (30). An example of the combination of proteolysis and lipolysis is enzymatically modified LDL (E-LDL), which is generated by treating LDL with a protease, such as matrix metalloproteinase 9 or cathepsin H, and cholesterol esterase (31–33).

Extensive oxidation can result in the fragmentation of apoB (34). Oxidation also leads to changes in the lipoprotein lipids, leads to the generation of malondialdehyde adducts in the lysine residues of the proteins, and induces the generation of oxidation-specific epitopes on the lipoproteins. Unlike proteolytic and lipolytic modifications, oxidation decreases the interaction of lipoproteins with proteoglycans. However, oxidized LDL (oxLDL) has been shown to bind to decorin-coated collagen via lipoprotein lipase thereby leading to extracellular accumulation of oxLDL (35). OxLDL also induces foam cell formation via interaction with various scavenger receptors on macrophages (36, 37).

Phospholipase A2 (PLA2) is an enzyme that hydrolyzes phospholipids generating non-esterified fatty acids (NEFAs) and lysophospholipids. PLA2 comprises several subtypes and can be found extracellularly as secreted PLA2s, intracellularly as cytosolic PLA2s, and in the bloodstream as lipoprotein-associated PLA2 (Lp-PLA2) (38). Lp-PLA2 is produced by hepatocytes, and also by inflammatory cells such as macrophages, foam cells, and mast cells, as well as T-lymphocytes in atherosclerotic plaques, and in the circulation it is mainly associated with LDL (39, 40). The various PLA2s have distinct specificities, group IIa, group V, and group X PLA2s being able to avidly hydrolyze phosphatidylycerol on LDL particles, while Lp-PLA2 preferably hydrolyzes oxidized phospholipids. Lp-PLA2 and several types of secretory PLA2s have been found in atherosclerotic plaques and in the normal arterial intima (38, 41–43). Modification of LDL, IDL, and VLDL with PLA2 increases their affinities to proteoglycans in vitro (44, 45), and thereby potentially enhances the retention of LDL particles in the vessel wall. PLA2-modified LDL also promotes macrophage foam cell formation (46, 47).

Treatment of LDL with an enzyme secreted by different cell types within the arterial intima, namely the sphingomyelinase (SMase), leads to conformational changes in apoB-100 and induces lipoprotein particle aggregation with ensuing increased proteoglycan binding (44, 48, 49). Secretory SMase implicated in atherogenesis has an acidic pH optimum, but can hydrolyze oxidized, PLA2-treated, or proteolysed LDL at neutral pH (30, 49). In addition, VLDL particles appear to be very susceptible...
to hydrolysis and aggregation by SMase (50, 51). Interestingly, ceramide, the lipolytic product of SMase action, is found exclusively in very large aggregates (49), such as those formed in vitro by modification of LDL by SMase at pH 5.5-6 (48). Generally, the sizes of LDL aggregates after in vitro modification differ substantially depending on the type of modification and the conditions used (48, 52). Although the aggregate size can affect aggregate uptake by, e.g., leukocytes (53), no studies have been performed to systematically study the effect of aggregate size on their pro-inflammatory properties either in vitro or in vivo.

Hydrolysis of the core lipids (cholesteryl esters and triglycerides) of lipoproteins has the potential to induce the generation of large amounts of NEFAs. The lipolytic hydrolysis is enhanced if the surface of the particles is also modified, e.g., by proteolysis, which allows penetration of some of the core lipids into the surface membrane of the lipoproteins (54). The E-LDL is an example of such multiply modified lipoprotein and antibodies generated against E-LDL bind to extracellular lipids in atherosclerotic lesions (55). Hydrolysis of cholesteryl esters has the potential to generate large amounts of cholesterol and lead to the generation of cholesterol crystals (56), which are a typical feature of very advanced atherosclerotic lesions (14). More recently, small cholesterol crystals have been identified also in early atherosclerotic lesions (57).
Complement

The complement system is a tightly regulated proteolytic cascade, a key component of innate immunity comprising over 30 soluble and membrane-bound proteins that responds rapidly to clear invading pathogens and damaged host cells, as well as to limit tissue destruction and initiate tissue healing. Complement activation is triggered by exposure to endogenous danger molecules that are released from damaged or dying cells and called danger-associated molecular patterns (DAMPs) (58). Depending on the initiation, the complement cascade follows either the lectin, classical, or alternative pathway. While these pathways have different activation cascades, they all converge downstream with the formation of their respective Complement (C) 3 convertases and the generation of C3a and C5b. If the complement activation is of sufficient magnitude, the membrane attack complex C5b-9 is formed. This important innate immune effector has pore-forming, lytic properties designed to destroy pathogens and damaged cells (59–61).

Circulating C3 levels were found to be significantly elevated in patients having familial hypercholesterolemia with subclinical coronary atherosclerosis, however, there was no correlation between circulating C3 levels and increased plaque burden, indicating a local regulation of the C3 in atherosclerotic arteries (62). Indeed, active components of the C3 complement are found within the extracellular matrix of human arteries (63). Complement components, including C3 were also identified in extracellular lipoproteins isolated from human carotid atherosclerotic lesions (56), and E-LDL was shown to colocalize with C5b-9 in human atherosclerotic lesions (55). Potential triggers of complement activation in the arterial wall include modified lipoproteins, cholesterol crystals, antigen-antibody immune complexes, C-reactive protein (CRP), and apoptotic cells [reviewed in (59, 63–65)]. Importantly, aggregated and fused lipoproteins isolated from human atherosclerotic lesions possess complement-activating properties (66). These particles do not contain immunoreactive apoB-100 but contain both esterified and unesterified cholesterol, and have sizes ranging from 100 to 500 nm (33). E-LDL with or without bound CRP, oxLDL, malondialdehyde-LDL, and oxLDL-immune complexes have been shown to induce complement activation [reviewed in (67)]. E-LDL, but not oxLDL, can trigger C1 activation and bind complement components (68, 69). Factor H, a major complement inhibitor, colocalizes in human atherosclerotic lesions with C3d in the subendothelial proteoglycan-rich layer, while C5b-9 is found in deeper areas of atherosclerotic lesions suggesting that in different areas of the lesions the components may differ in their abilities to regulate complement activation (63).

Foam Cell Formation

Foam cells are the histological hallmark of atherosclerotic lesions from the very beginning of the lesion development, and their contribution to atherogenesis remains throughout the lesion progression (13, 15). They are derived mostly from macrophages that take up modified and aggregated lipoproteins and lipoprotein-immune complexes via several different mechanisms (36). In addition to the macrophages, also vascular SMCs take up modified lipoproteins and can become foam cells (70, 71). The various uptake mechanisms include scavenger receptors that are important particularly in the uptake of oxLDL. Fc-gamma receptors interacting with immune complexes, cell surface proteoglycan-aided uptake of PLA2-modified LDL, and phagocytosis of aggregated LDL and even cholesterol crystals (46, 72–75). Native VLDL remnant particles have been shown to induce foam cell formation through the VLDL receptor pathway in macrophages, and modification of VLDL particles by acetylation leads to macrophage foam cell formation via scavenger receptor-mediated uptake of the modified particles (76).

A specific uptake mechanism in macrophages has been reported for large LDL aggregates, such as Smase-modified LDL particles. Thus, aggregated LDL triggers the formation of extracellular surface-connected compartments into which the macrophages (77) and dendritic cells (78) secrete lysosomal enzymes, such as lysosomal acid lipase (LAL) (78–80). The process leads to a partial hydrolysis of the aggregated LDL outside the cells and to internalization of the partially hydrolyzed lipoproteins into lysosomes, where they are fully hydrolyzed. Actin polymerization and Toll-like receptor (TLR) 4 activation drive the intracellular catabolism of the aggregates (80, 81). In addition, treatment of LDL with macrophage-conditioned media containing catalytically active LAL induces LDL fusion and lipid droplet formation in VSMCs (54). LAL activity may be particularly prominent in the macrophage-rich acidic microenvironments observed in human atherosclerotic lesions (82).

Once lipoproteins have reached the lysosomes, their components are completely hydrolyzed (Figure 2). Importantly, cholesteryl ester hydrolysis by LAL results in the formation of unesterified cholesterol, which will then be re-esterified in the cytoplasm and packaged into intracellular lipid droplets characteristic of foam cells (83). Uptake of aggregated LDL has been shown to lead to accumulation of ceroid, a product of lipid oxidation consisting of protein-lipid complexes, in lysosomes (84). Lysosomal oxidation is likely mediated by iron and can be inhibited by cysteamine (85). On the other hand, uptake of oxLDL can result in lipid accumulation in the lysosomes (86, 87) and lead to the formation of cholesterol crystals in the lysosomes (88). However, the transformation of macrophages into foam cells may reduce their atheroinflammatory potential (89).

In vascular SMCs, foam cell formation due to uptake of native and modified VLDL was shown to depend on the activity of lipoprotein lipase (90), while the LDL receptor-related protein 1 plays a role in the uptake of aggregated LDL (91). Aggregated LDL particles increase the release of the soluble form of LDL receptor-related protein 1 from cultured vascular SMCs, and from human atherosclerotic plaques in an ex vivo model (92). Interestingly, the level of the soluble LDL receptor-related protein 1 in the circulating blood is increased in patients with coronary artery disease (92, 93). When compared with cultured human macrophages, cultured human SMCs express relatively low levels of LAL (94). Accordingly, in SMC foam cells, the ingested neutral lipids tend to accumulate within lysosomes, while in macrophages they appear as cytosolic droplets.
Lorey et al. Modified Lipoproteins Induce Inflammation

FIGURE 2 | Effects of lipoproteins on macrophages and endothelial cells. Upon phagocytosis, modified lipoproteins are hydrolyzed in the lysosomes of macrophages. Cholesterol is then transported to the ER where it is packaged in lipid droplets for storage. It can also crystallize in the lysosomes, leading to lysosomal dysfunction and the release of reactive oxygen species (ROS) and cathepsins, which in turn activate cytosolic inflammasomes. NF-κB signaling is induced and the activated macrophages secrete leukocyte chemotactic molecules, pro-as well as anti-inflammatory cytokines, and proteases. In endothelial cells, lipoproteins can be transported through the cell via transcytosis, mediated by binding to scavenger receptor B1 (SR-B1) and activin-like kinase 1 (ALK1). If the lipoproteins have been modified, they can also bind to lectin-type oxidized LDL receptor 1 (LOX-1) and then targeted to the lysosomes after internalization. LOX-1 activation leads to decrease in nitric oxide (NO) and increase in reactive oxygen species (ROS), the latter being able to trigger NLRP3 inflammasome activation. Activated endothelial cells increase the expression of adhesion molecules which accelerates leukocyte extravasation, and they also secrete leukocyte chemotactic factors, as well as pro-inflammatory cytokines.
While complement activation is usually regarded to be pro-atherogenic, complement plays also a smoothing role in mediating the effects of foam cell formation. Thus, while the complement component C1q recognizes and opsonizes modified forms of LDL and promotes phagocytosis and efferocytosis in macrophage foam cells (95, 96), when bound to acLDL or oxLDL it reduces the release of proinflammatory cytokines from macrophage foam cells and atherosclerosis in mouse models (97). In addition, C1q downregulates both the levels and activities of apoptosis-related proteins in human and mouse macrophage foam cells, thereby leading to a measurable increase in the survival of these cells, which, again, could slow down the build-up of the necrotic core in the atherosclerotic plaques (95). Further, factor H, the main regulator of the alternative complement activation pathway, has been shown to bind to human monocytes and macrophage foam cells and has the potential to reduce complement activation and inflammation, and to increase the binding of apoE to these cells. It further increased cholesterol efflux, and cholesterol-loaded macrophages displayed reduced transcription of proinflammatory/proatherogenic factors and increased transcription of anti-inflammatory/anti-atherogenic factors, thereby indicating that apoE and factor H interact with monocytic cells in a concerted action and that this interaction tends to reduce complement activation and inflammation in atherosclerotic lesions (98).

**MODIFIED LIPOPROTEINS INDUCE INFLAMMATION VIA INNATE IMMUNE CELLS**

Continued accumulation of immunogenic modified lipoproteins and the attendant pro-inflammatory reactions in the arterial intima result in the development of atherosclerotic lesions (99). Thus, atherosclerosis is driven by a chronic, low-grade inflammation of the vascular wall that continuously attracts immune cells into the developing atherosclerotic plaques (100).

As the first step in atherogenesis, native lipoproteins enter the intima by transcytosis, get trapped and modified by enzymes secreted by resident macrophages and mast cells, as described above. Minimally modified lipoproteins from the circulation or modified lipoproteins from the intima can be internalized by ECs via the lectin-like oxidized LDL receptor 1 (LOX-1) and be destined for lysosomal degradation, which activates the ECs and initiates endothelial dysfunction [Figure 2, reviewed in (101)]. ECs also get activated by secreted cytokines and chemoattractants derived from activated intimal macrophages (101). The activated endothelium then secretes chemoattractants and increases the expression of adhesion molecules so aiding the tethering, rolling, and adhesion steps of the leukocyte diapedesis process. Within the intima, monocytes differentiate into macrophages or DCs, and the naïve T cells mature. Macrophages can be pro-inflammatory (M1) or anti-inflammatory/pro-resolving (M2) phenotype, and their phenotype can change in response to alterations in their microenvironmental conditions [reviewed in (102)]. The above widely used dichotomous classification of macrophages into pro- and anti-inflammatory phenotypes provides a useful framework, but only represents the opposite ends of a wide spectrum of phenotypes which includes an ever-increasing number of subtypes, as revealed by modern single-cell omics technologies. The polarization of macrophages is mediated by a plethora of extrinsic factors such as cytokines, and also by intrinsic regulatory mechanisms, such as increased glycolysis, all of which in various combinations may alter the gene expression profile and reactivity of the macrophages involved [reviewed in (102, 103)]. The metabolic changes in macrophages can be altered by ligand-activated transcription factors such as peroxisome proliferator-activated receptors (PPARs) and liver X receptors. Once activated, these receptors inhibit the pro-inflammatory transcription factors NF-κB and AP-1 and thus downregulate the expression of pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF) (104).

DCs and macrophages phagocytise modified LDL, which the DCs then present to T cells, while the activated macrophages start to secrete cytokines, chemokines, and enzymes, thus further activating the endothelium and leading to increasingly diverse and severe modifications of the trapped lipoproteins (Figure 2).

The modifications of the trapped lipoproteins lead to the formation of DAMPs, which are recognized by pattern recognition receptors (PRRs) located on the surface of antigen-presenting cells, and also on the surfaces of non-immune cells, such as the ECs. The membrane-bound PRRs include toll-like receptors (TLRs), scavenger receptors (72), and the receptor for advanced glycation end-products (RAGE) (105). When activated, the TLRs recruit adapter proteins to activate two main pathways, a MyD88-dependent and a TRIF-dependent pathway, that lead to the production of inflammatory cytokines or type I interferons, respectively (106). Several TLRs have been shown to play important roles in atherogenesis [reviewed in (106)].

Another set of PRRs, the NOD-like receptors (NLRs), are located in the cytoplasmic compartment of cells. Once a cell senses intracellular damage-associated events such as membrane damage, lysosomal rupture, or mitochondrial damage, it initiates the assembly of the NLR family pyrin domain containing 3 (NLRP3) inflammasome (107). Inflammasomes are large cytosolic multiprotein complexes, and once assembled, they induce the activation of inflammatory responses, including proteolytic activation and secretion of the proinflammatory cytokines IL-1β and IL-18 (108). Especially the NLRP3 inflammasome plays a role in atherosclerotic plaque formation [reviewed extensively in (108)]. Inflammasome-mediated activation of caspase-1 can also initiate a form of lytic and highly inflammatory cell death called pyroptosis, in which the protein gasdermin D is cleaved, after which its N-terminus oligomerizes and forms pores in the cell membrane (109). Crystalline cholesterol induces lysosomal damage, and it was the first NLRP3 activator associated with atherosclerosis (57, 75). Crystalline cholesterol can be formed extracellularly from lipoprotein aggregates in the intima, and intracellularly during the lysosomal degradation of modified lipoproteins.

Several studies have shown that modified lipoproteins can activate leukocytes and trigger a pro-inflammatory response (18, 110). This response is leading to the secretion of a plethora
of cytokines, chemokines, growth factors, and lipids. The most important ones in the context of this review are shown in Table 1, and the individual responses of cell types to specific modified lipoproteins discussed below are summarized in Table 2.

**Vortexed and Acetylated Lipoproteins**

Acetylated LDL (acLDL) and vortexed LDL (vxLDL) are models of modified lipoproteins that have been used to study intracellular lipid accumulation in macrophages, SMCs, and ECs (161–165). Vortexing of LDL leads to aggregation of the particles, but these modifications do not change the lipid moiety of LDL particles and, therefore, experiments in which they have been used provide information merely on their effects on lipid loading on macrophages. Treatment of macrophages with modified LDLs that induce foam cell formation, including acLDL, results in upregulation of genes involved in the inflammation and immune responses (110).

VxLDL induces mitochondrial dysfunction in macrophages, a known activator of the NLRP3 inflammasome (166). Persson et al. studied the basal and inducible cytokine expression in primary human macrophages loaded with cholesterol using vxLDL and they observed that the cholesterol contained in the vxLDL did not affect IL-1β secretion, while the secretion of TNF, IL-6, and IL-8 were significantly decreased (167). However, the amount or composition of neutral lipids in the vxLDL did not affect cellular activation by exogenous TNF, making it likely that lipid loading attenuates cytokine secretion during basal conditions, and that the effects can be overruled by TNF during an acute inflammation (167). Sabeva et al., however, reported that IL-1 and IL-6 signaling can be induced by vxLDL in THP-1-derived macrophages (135). Depending on the macrophage polarization, inflammatory responses to cholesterol loading can vary vastly, as recently shown by comparing the inflammatory responses in M1-like and M2-like macrophages upon acLDL loading (89).

**Circulating Modified Lipoproteins**

Electronegative LDL (LDL-), carboxylated LDL (cLDL) or HDL, glycosylated LDL (AGE-LDL), and mildly oxidized LDL are found in the circulation, and they can initiate foam cell formation in cell culture [reviewed in (168–170)].

LDL- is a naturally occurring, minor form of modified LDL in plasma, and it can be isolated based on its differing size, density, and charge. Compared to native LDL, LDL- has similar oxidation levels, but it differs in its lipid and protein compositions and in its apoB-100 conformation. LDL- also has higher phospholipidic activities, higher aggregation levels, and higher proteoglycan binding affinity than LDL (133).

In ECs, LDL- increases TNF-induced inflammatory responses, such as the expression of transcription factors nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and Activator Protein 1, the expression of Vascular Cell Adhesion Molecule 1 (VCAM-1) (137), and the secretion of the chemotactic factors IL-8 and Monocyte Chemotactic Protein 1 (MCP-1) (139), C-X-C Motif Chemokine Ligand 1, the cytokine IL-6, and the growth factors platelet-derived growth factor, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Vascular Endothelial Growth Factor (138, 140, 141).

**Table 1 | Main cellular mediators of athero-inflammation.**

| Name       | Function in atherogenesis |
|------------|---------------------------|
| IL-1β      | Drives inflammation during atherogenesis and the evolution of advanced atheroma (108, 111, 112) |
| IL-1α      | Promotes remodeling during early atherogenesis (108, 111) |
| IL-6       | Pro-inflammatory in chronic inflammation, anti-inflammatory in acute inflammation (112–115) |
| TNF        | Pro-inflammatory, activates leukocytes, induces endothelial dysfunction (115, 116) |
| IL-8       | Pro-inflammatory, neutrophil and monocyte chemotactic factor (117, 118) |
| IL-10      | Anti-atherogenic, downregulates production of TNF and ICAM-1 (115, 119) |
| IL-35      | Anti-atherogenic (120) |
| IL-12      | Pro-atherogenic, elevated plasma levels (120) |
| IL-18      | Pro-inflammatory (112) |
| IFN-γ      | Pro-inflammatory, multiple roles at different stages of atherogenesis (121) |
| MCP-1      | Pro-inflammatory, chemotactic activity for monocytes and basophils (122) |
| CCR2       | Chemokine receptor for MCP-1 |
| CXCL1      | Pro-inflammatory, chemotactic factor for monocytes (122) |
| GM-CSF     | Induces a pro-inflammatory phenotype in macrophages (123, 124) |
| TGF-β      | Pro-inflammatory (125), but also atheroprotective (126) |
| PDGF       | Intra-plaque angiogenesis, elevated in atherosclerosis (127) |
| VEGF       | Intra-plaque angiogenesis, elevated in atherosclerosis (127) |
| ICAM-1     | Allows rolling and adherence of leukocytes to the endothelium (122) |
| VCAM-1     | Allows rolling and adherence of leukocytes to the endothelium (122) |
| MMP's      | Promote plaque instability by degrading extracellular matrix proteins (112) |
| p38MAPK    | Transcription factor for proinflammatory TNF and IL-1 family signaling (128) |
| NF-κB      | Transcription factor for proinflammatory TNF and IL-1 family signaling (128) |
| AP-1       | Transcription factor for cytokines and growth factors in innate immune response (128) |
| ROS        | Pro-inflammatory, pro-atherogenic or atheroprotective depending on the context (129) |
| AA         | AA metabolites mediate initiation and resolution of inflammation and have been linked to the pathophysiology of many chronic inflammatory diseases (130) |
| PAI-1      | Vascular PAI-1 excess is thought to promote the development of intravascular thrombosis and atherosclerosis (131) |
| PECAM-1    | Adhesion factor, promotes leukocyte extravasation (132) |
| E-Selectin | Adhesion factor, promotes leukocyte extravasation (132) |
| P-Selectin | Adhesion factor, promotes leukocyte extravasation (132) |

Interleukin (IL), tumor necrosis factor (TNF), interferon-γ (IFN-γ), monocyte chemoattractant protein-1 (MCP-1), C-C chemokine receptor type 2 (CCR2), C-X-C Motif Chemokine Ligand 1 (CXCL1), granulocyte-macrophage colony-stimulating factor (GM-CSF), transforming growth factor β (TGF-β), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), matrix metalloproteinases (MMPs), p38 mitogen-activated protein kinase (p38MAPK), nuclear factor kappa-light-chain-enhancer of the activated B-cell (NF-kB), activator protein 1 (AP-1), reactive oxygen species (ROS), arachidonic acid (AA), plasminogen activator inhibitor-1 (PAI-1), platelet endothelial cell adhesion molecule-1 (PECAM-1).
TABLE 2 | Cellular responses to selected modified lipoproteins.

| Cell type | Response |
|-----------|----------|
| vxLDL     | Macrophages IL-1β secretion (133), IL-6 secretion (133, 134), IL-10 secretion (133), TNF secretion (135) |
| acLDL     | Macrophages IL-1β secretion (133), IL-6 secretion (133, 134), IL-10 secretion (133), CS secretion (136) |
| LDL(-)    | ECs Expression of adhesion molecule VCAM-1 (137, 138), ICAM-1 (139), MCP-1 (138, 139), PDGF (140), IL-6 and GM-CSF secretion (140, 141), IL-8 (138-140) |
|           | Macrophages IL-1β secretion (133), IL-6 secretion (133, 134), TNF secretion (134), IL-8 secretion (134), IL-10 secretion (133) |
|           | Dendritic cells IL-12 and TNF production (142) |
|           | Monocytes IL-6 secretion (133, 134), TNF secretion (134), IL-8 secretion (134) |
| E-LDL     | ECs Expression of IL-8 (143) Expression of IL-8 (83), ICAM-1, PECAM-1, P-selectin, and E-selectin (144) |
|           | Macrophages Strong synthesis of MCP-1, mild release of IL-6 (145) |
|           | Dendritic cells TNF secretion (142) |
| LAL-LDL   | Macrophages IL-8 secretion, activation of transcription factors p38 MAPK and NF-κB (146) |
|           | ECs IL-6 and GM-CSF secretion (133, 140, 141), upregulation of E-Selectin, ICAM-1, VCAM-1 (147) and release of arachidonic acid (147) |
|           | Macrophages IL-1β secretion (56). |
|           | Macrophages SMase-LDL treatment increases the lipopolysaccharide-induced secretion of TNF, IL-6, and MCP-1 (84) |
| oXLDL     | ECs LOX-1 activation and subsequent activation of NF-κB, increase in ROS/decrease in NO, increased expression of MCP-1, VCAM-1, ICAM-1, P-selectin, decreased expression of TGF-β, and apoptosis (148, 149). |
|           | Macrophages IL-1β secretion (133), IL-6 secretion (133, 134), IL-10 secretion (133), CS secretion (136) |
| oxVLDL    | ECs Expression of IL-15, MMP-2, MIP, downregulated expression of TGF-β, ROS production (150), MCP-1 upregulation (151) |
|           | Macrophages MCP-1 upregulation (151) |
|           | Monocytes Increased MCP-1 expression (152) |
| cLDL      | ECs ICAM-1 and VCAM-1 expression (153) |
| cHDL      | ECs Expression of VCAM-1 and ICAM-1 and increased monocyte adhesion (154) |
| AGE-LDL   | ECs Expression of ICAM-1, VCAM-1 (155-157), IL-6 secretion (158), TGF-β, TNF, and MCP-1 synthesis (155, 157) |
|           | Macrophages IL-6 secretion (158) |
| VSMCs     | Increased ROS and expression of MCP-1 (160) |
| Monocytes | Increased expression of MCP-1 receptor CCR2 (159) |

Vortexed LDL (vxLDL), acetylated LDL (acLDL), electronegative LDL (LDL(-)), enzymatically modified LDL (E-LDL), lysosomal acid lipase-modified LDL (LAL-LDL), phospholipase A2-modified LDL (PLA2-LDL), sphingomyelinase-modified LDL (SMase-LDL), oxidized LDL (oxLDL), oxidized VLDL (oxVLDL), carbamylated LDL (cLDL), carbamylated HDL (cHDL), advanced glycation end-product-modified LDL (AGE-LDL), endothelial cells (ECs), interleukin (IL), tumor necrosis factor (TNF), complement component 3 (C3), vascular cell adhesion protein 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), platelet-derived growth factor (PDGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), platelet endothelial cell adhesion molecule (PECAM-1), lectin-type oxidized LDL receptor 1 (LOX-1), nuclear factor kappa-light-chain-enhancer of the activated B-cell (NF-κB), reactive oxygen species (ROS), matrix metalloproteinase (MMP), macrophage migration inhibitory factor (MIF), transforming growth factor β (TGF-β).

In monocytes and macrophages, LDL(-) directly induces priming, inflammasome activation with subsequent IL-1β release (171, 172), as well as secretion of IL-6, IL-8, and TNF (134). Puig et al. compared the effects of oxLDL, vxLDL, and acLDL with those of LDL(-) on THP1-derived macrophages and found that while oxLDL induced a more pronounced IL-1β release, LDL(-) induced a stronger release of IL-6, IL-10, and GM-CSF than did other modified LDLs (133). Interestingly, unlike other modified LDL preparations, LDL(-) induced a very strong triglyceride (TG) accumulation in lipid droplets of macrophages (133), a finding which may have clinical significance in that macrophages isolated from human atherosclerotic aorta show significant accumulation of TGs (173).

Protein carbamylation is a post-translational modification of proteins involved in a variety of disease states including inflammation, impaired renal function in chronic kidney disease, and, moreover, elevated levels of carbamylated proteins are present in smokers. Carbamylation has been mechanistically linked to atherosclerosis [reviewed in (174)], especially in patients with chronic renal failure who have vastly higher levels of carbamylated LDL in serum and a higher ASCVD risk (175). It has also been shown to induce endothelial dysfunction (176), increase the expression of adhesion molecules (153), the oxidative stress, and DNA damage in endothelial progenitor cells (177). Also carbamylated HDL increases monocyte adhesion to ECs via inducing NF-κB activation and the expression of VCAM-1 and the intercellular adhesion molecule-1 (ICAM-1) (154). Carbamylation also renders LDL more prone to oxidation, and LDL with both modifications has more pro-atherogenic effects on ECs and macrophages than either modification alone (178).

Non-enzymatic modifications of proteins by glucose are called advanced glycation end-products (AGEs), and they are formed at accelerated rates in hyperglycemic diabetic patients. AGEs can also form on lipids, as evidenced by the observation of lipid-linked AGEs in LDL particles derived from individuals with or without diabetes (179). The AGE-products include circulating AGE-peptides which derive from the catabolism of AGE-modified tissue proteins, and, moreover, AGE-modified...
LDL is formed by direct reaction between native LDL and circulating reactive AGE-peptides (179). The AGEs, among them also the AGE-LDL, damage vascular cells, one pathway being their interaction with their purported receptors on vascular ECs, SMCs, and macrophages. Among the ensuing implicated diverse pro-atherogenic processes, those leading to endothelial dysfunction have received much attention (155). The adverse endothelial effects include apoptosis (180), reduced nitric oxide synthesis, increased production of reactive oxygen species, and increased expression of (VCAM)-1 (156). Moreover, AGE-LDL particles induce IL-6 secretion by ECs and macrophages (158).

**Phospholipolytically Modified Lipoproteins**

The lipolytic products generated by the action of PLA₂, fatty acids and lysophospholipids, induce proinflammatory responses in cultured human umbilical vein ECs (181). PLA₂-treated LDL induces exocytosis of the Weibel-Palade Bodies, an early-phase endothelial inflammatory response from ECs in a lysophosphatidylcholine (LPC)-dependent manner (182). LPC acts as a find-me/eat-me signal, which belongs to a group of soluble mediators released by apoptotic cells that attract phagocytes into the tissue (183). PLA₂-LDL has also been shown to upregulate the adhesion factors E-selectin, ICAM-1, and VCAM-1 in ECs (147). In primed human macrophages, PLA₂-treated LDL and especially LDL and VLDL treated with both PLA₂ and LAL have shown to elicit a strong induction of NLRP3-dependent IL-1β secretion (56).

Treatment of LDL particles with SMase, which is secreted by several cell types within the arterial wall, leads to the generation of ceramide and to conformational changes in apoB-100 that induce particle aggregation and increased proteoglycan binding (48–50). These effects could be alleviated by treatment of the LDLs with an apoA-I mimetic peptide prior to the hydrolysis (184). SMase-LDL has been shown to induce the secretion of TNF, IL-1β, IL-6, and the chemotactant MCP-1 from human macrophages derived from cultured THP-1 monocytes (56, 84). LDL which has been lipolytically modified by secretory PLA₂ or SMase potentiates the cellular release of proinflammatory lipid mediator arachidonic acid, and triggers activation of the cytoplasmic PLA₂ in human THP-1 monocytes (185).

Regarding SMase, another point to consider is that it is expressed by macrophages. Endogenous sphingomyelins on the cell membrane can be hydrolyzed, and the generated ceramides can accumulate or be converted into numerous metabolites [reviewed in (186)]. These metabolites are involved in a variety of processes connected to cardiovascular health, they modulate the signaling and metabolic pathways driving insulin resistance, TG production, apoptosis, and fibrosis [reviewed in (187)]. Cellular uptake of SMase-modified LDL brings substantial amounts of ceramides into lysosomes, and, moreover, as LDL contains significant amounts of SM, uptake of modified LDL can also in other ways affect the sphingomyelin pool in macrophages and thus the concentrations of ceramides in them. Kinscherf et al. showed in their early work that loading of macrophages with oxLDL and acLDL delivers a substantial amounts of sphingomyelin into the cells and also stimulates ceramide formation in them (188).

**Enzymatically Core-Modified Lipoproteins**

Modifications of the lipoprotein core at neutral pH are more difficult to perform due to the protective surface monolayer of the lipoproteins. Therefore, the core-modifying treatments are usually preceded by a modification of the surface. To generate enzymatically modified LDL (E-LDL), LDL is first treated with a protease and subsequently with cholesterol esterase. Such multiply-modified LDL has been detected by immunohistochemical means in human atherosclerotic lesions at all stages of lesion development (55). Treatment of ECs with E-LDL leads to the expression of IL-8 (143), induces the adhesion of monocytes and T lymphocytes to EC monolayers, and stimulates the upregulation of the adhesion factors ICAM-1, platelet-endothelial cell adhesion molecule-1 (PECAM-1), P-selectin, and E-selectin (144). In aortic SMCs, E-LDL upregulates the expression of ICAM-1, which correlates with increased adhesion of T lymphocytes (144). It also strongly induces SMC foam cell formation and upregulates the expression of lectin-like oxLDL receptor 1 (LOX-1) with ensuing increase in the uptake of oxLDL (189).

In macrophages, E-LDL induces strong secretion of MCP-1 and mild release of IL-6 (145). It also promotes monocytic differentiation into dendritic cells, and, when dendritic cells are treated with CRP and/or E-LDL, the production of IL-12 and TNF is significantly increased, and a strong Th1 reaction and T cell proliferation are elicited (142).

LAL hydrolyzes TGs and cholesteryl esters in the core of the lipoprotein particles. LAL is an essential lysosomal enzyme and its deficiency leads to cholesteryl ester storage disease (190). Expression of LAL has been shown to become downregulated in several cell types when the cells are loaded with modified LDL (191, 192). LAL is also secreted from activated macrophages and can then act on lipoproteins also extracellularly (54). Treatment of macrophages with LAL-LDL activates the transcription factors p38 MAPK and NF-κB, induces the secretion of IL-8 (146), and may also promote vascular dysfunction and atherogenesis [reviewed in (193)]. LDL and VLDL, when treated first with enzymes that hydrolyze the particle surface before treatment with LAL, are able to trigger a robust, NLRP3-mediated IL-1β secretion in human macrophages (56).

VLDL remnants treated with lipoprotein lipase to hydrolyze the TGs have been shown to induce increased expression of TNF, IL-1β, and IL-8 over native VLDL or lipoprotein lipase, with concurrent activation of NF-κB and activator protein 1 in peripheral blood mononuclear cells and THP-1 monocytes (194).

**Oxidized Lipoproteins**

Oxidation is the most studied form of lipoprotein modification, and the pro-inflammatory effects of oxidized phospholipids in inflammation and various inflammatory diseases are well established (195). OxLDL acts as a DAMP and triggers sterile inflammatory responses (195). In ECs it causes endothelial dysfunction and induces a pro-inflammatory and pro-thrombotic state (196). It also enhances monocyte chemotaxis and adhesion to EC in culture (197). The uptake of oxLDL by macrophages is mediated by scavenger receptors such as CD36, and it induces the assembly
of a TLR4/TLR6 heterodimer, and results in NF-κB signaling and priming of these cells for inflammasome activation (198). OxLDL uptake by CD36 additionally results in intracellular cholesterol crystallization and can thereby directly activate the NLRP3 inflammasome in macrophages (88). Both minimally oxidized LDL and more highly oxidized LDL cause the secretion of pro-inflammatory cytokines by macrophages (70, 71) by activating TLR4 (199, 200). Li et al. showed in THP-1 monocytes that oxLDL and oxHDL increases the expression of NLRP3 and activates caspase-1 and induces IL-1β and IL-18 secretion in a dose-dependent manner (201). However, other studies have shown that oxLDL inhibits the production of inflammatory cytokines by macrophages in response to inflammatory stimuli, such as LPS (202). More recently, it was shown that oxLDL, as well as oxHDL3, reduces the secretion of mature IL-1β by inhibiting the activation of the NLRP3 inflammasome induced by known inflammasome activators including the acute-phase serum amyloid A protein, ATP, nigericin, and monosodium urate crystals (203). By binding to LOX-1 on SMCs, oxLDL can also induce SMC transition to an inflammatory phenotype. Thus, treating cultured SMCs with oxLDL stimulates the expression of the chemokines MCP-1 and C-X-C Motif Chemokine Ligand 1, the cytokine TNF, and the cell adhesion molecule VCAM-1 [reviewed in (204)].

OxLDL can also induce pyroptosis in macrophages (205) and ECs (206), and oxLDL-induced pyroptosis has also been implicated in endothelial dysfunction and vascular SMC foam cell formation [reviewed in (109)].

OxLDL is also able to induce a novel form of cell death coined ferroptosis, which is linked to atherogenesis (207, 208). Bai et al. showed that some of the key morphological features of ferroptosis, such as mitochondrial shrinkage, increased iron content, increased release of lactate dehydrogenase, and reduced expression of the solute carrier family 7 member 11 and glutathione peroxidase 4 were induced by oxLDL in mouse aortic ECs to a comparable amount achieved with the ferroptosis inducer erastin; the phenotype was rescued by co-stimulation with ferroptosis inhibitor ferrostatin-1 (209). Further, oxLDL- and erastin-treated cells had similarly increased levels of markers of intracellular lipid peroxidation, such as total ROS, lipid ROS, lipid peroxide, and malondialdehyde, while treatment with ferrostatin-1 downregulated the generation of these lipid peroxidation products (209). Similar induction of ferroptosis by oxLDL was observed in human coronary artery ECs (210).

While minimally oxidized LDL is found in circulation, the vast majority of circulating oxLDL is bound to antibodies and found as oxLDL immune complexes, which can prime dendritic cells and macrophages for inflammasome activation (211). While the circulating immune complexes may be too large to cross an intact endothelium, immune complexes can also be formed within the arterial intima (212). Interestingly, immune complexes composed of oxLDL and anti-LDL IgG antibodies can trigger activation of cultured human mast cells, an innate immune type of cell present in human atherosclerotic lesions, and, when activated, capable of proteolytically modifying LDL and HDL particles (213, 214).

In ECs, oxidized VLDL initiates the expression of the fibrinolysis inhibitor plasminogen activator inhibitor-1 and stress response protein heat shock factor 1 compared to the effects obtained with VLDL or LDL (215), and induces endothelial apoptosis (216). It also induces expression of IL-15, matrix metalloprotease-2, macrophage migration inhibitory factor, as well as downregulated expression of transforming growth factor beta (TGF-β) (150). In macrophages, both oxidized VLDL and its remnants induce foam cell formation that can be attenuated by pre-incubation with TGF-β (217). In both monocytes and macrophages, oxidized VLDL induces the expression of MCP-1 (151, 152).

Oxidized HDL (oxHDL) plasma levels have been shown to correlate with ASCVD and coronary artery calcification [recently reviewed in (218)]. OxHDL induces endothelial dysfunction in ECs by a positive feedback mechanism in which an oxidative burst generates oxHDL from native HDL, activates LOX-1 which in turn increases the expression of NADPH oxidase 2, TNF, and LOX-1 receptor at the endothelial plasma membrane (219). It has also been shown to decrease the expression of CD63 in macrophages, thus attenuating the ability of the cell to ingest modified lipoproteins (220, 221). OxHDL also binds to CD36 on platelets and induces proinflammatory and procoagulant effects (222).

**Neutrophil Extracellular Traps**

Another innate immune pathway contributing to vascular inflammation is neutrophil extracellular trap (NET) formation, also called NETosis (223). NETs are structures of chromatin filaments coated with histones, proteases, as well as granular and cytosolic proteins, which are ejected by activated neutrophils to immobilize and eliminate pathogens as a part of the first-line immune defense.

Recent research has revealed that NETosis is associated with the initiation and progression of various noninfectious diseases (224), and NETosis has also been shown to promote thrombosis (225). NETs have been found in vascular lesions such as atherosclerotic plaques (226), and infiltration of neutrophils into arteries during the early stages of atherosclerosis has been observed in hypercholesterolemic mice (227). One theory about the reason for NETs in plaques is that periodontal pathogens enter the bloodstream from severely infected periodontal tissues, then reach the inflamed atherosclerotic lesions where they can directly contribute to the development of the lesions [reviewed in (228)]. Non-infectious triggers such as LDL-derived cholesterol crystals might also induce NETosis in atherosclerosis. NETs prime macrophages, which in turn start to produce pro-IL-1β and IL-8 (117). Cholesterol crystals can bind to CD36 on the macrophages and thereby trigger inflammasome activation with the ensuing secretion of mature IL-1β. Thus, NETs may contribute to atherogenesis by initially activating macrophages (229, 230). Studies in apoE−/− mice with deletions of two neutrophil proteases showed attenuated NETosis as well as smaller atherosclerotic lesions, and lower systemic IL-1β levels, when compared to ApoE−/− mice expressing these proteases.
and to a lesser extent IgG, and B2 cells which can differentiate into subtypes, B1 cells which produce the majority of natural IgM plasma cells occurs after their activation. There are two main in this process.

Kato et al. demonstrated the appearance of oxLDL in vascular tissues and circulation even prior to atherosclerotic lesion development in apoE-KO mice (231). OxLDL as well as its various oxidized phospholipid components, especially oxPCs and LPC, mediate NETs formation and subsequent endothelial inflammatory responses in both HL-60-derived neutrophils and human polymorphonuclear neutrophils (232, 233).

ADAPTIVE IMMUNE SYSTEM RESPONSE AND AUTOIMMUNE COMPONENT

Adaptive immunity is heavily involved in atherogenesis [reviewed in (234)] and comprises a humoral component of specific antibodies produced by B cell-derived plasma cells, and a cellular component with T cells that either activate B cells or differentiate into effector T cells, which are matured by being presented antigens by antigen-presenting cells. Of the T cells, those expressing CD8 mature into cytotoxic CD8+ T cells and those expressing CD4 into helper CD4+ T cells or regulatory T cells. Both CD4+ and CD8+ T cells are recruited into atherosclerotic lesions and display signs of activation (235). On the other hand, the regulatory T cells comprise the only T cell subset that has only negative regulatory effects on the autoimmune response, and therefore also a dampening influence on atheroinflammation. The recruitment of regulatory T cells into the arterial intima is promoted by the activation of the nuclear receptor peroxisome proliferator-activated receptor γ (PPAR-γ), which can further exert anti-atherosclerotic effects by inhibiting the expression of various pro-inflammatory factors, improving the function of endothelial cells, inhibiting MCP-1 expression, and restraining the differentiation of monocytes into macrophages [reviewed in (236)].

T cells with a specificity for apoB-derived epitopes have been identified, so linking adaptive immune responses to the vascular retention of LDL (237). Vaccination of humanized atherosclerotic mice with two epitopes from human native apoB-100 that trigger T-cell activation protected the mice against atherosclerosis (238). T cells constitute about 10% of all cells in human plaques, and 70% of them have been described to be CD4+, and the remaining largely CD8+ T cells (239).

The final stage of B cell maturation into antibody-producing plasma cells occurs after their activation. There are two main subtypes, B1 cells which produce the majority of natural IgM and to a lesser extent IgG, and B2 cells which can differentiate directly into memory B cells (240). T cells and macrophages are found in all stages of atherosclerosis, whereas B cells are only occasionally found in the atherosclerotic plaques themselves. Rather, a larger number of B cells may be found in the adventitial layer of the arterial wall, where tertiary lymphoid organs can be formed (241). Resident B2-type lymphocytes isolated from human carotid atherosclerotic walls have been found to be mainly activated plasmablasts lacking terminal differentiation to plasma cells, and preferentially expressing IgG and IgA (242).

Functionally, the effects of B and T cells in atherosclerosis, the primary site of lipoprotein modification, are mixed. In a recent consensus paper (6) the involvement of lymphocytes is described as follows: Dendritic cells take up modified LDL and present specific epitopes such as apoB peptides to naive T cells, inducing their differentiation into CD4+ helper T cells (243). These CD4+ T cells, together with the specific cytokines that they secrete, provide help to B cells, and regulate the activity of other T cell subtypes. The pro-atherogenic role of interferon gamma (IFN-γ)-secreting Th1 cells and the anti-atherogenic effect of IL-10/TGF-β-secreting T regulatory cells are well established (244). Cytotoxic CD8+ T cells have been shown to promote atherogenesis (245). Hermansson et al. studied the mechanism of T cell recognition of LDL particles by generating T cell hybridomas from human apoB-100 transgenic mice that were immunized with human oxLDL, and found that none of the hybridomas responded to oxLDL, but, instead, to native LDL and isolated apoB-100. However, sera from these immunized mice contained antibodies against oxLDL, suggesting that T cell responses to apoB-100 aid B cells to generate antibodies against the epitopes present in both native LDL and oxLDL. ApoB-100-responding CD4+ T cell hybridomas expressed a single T cell receptor variable β chain, and immunization of humanized atherosclerotic mice with a peptide derived from that T cell receptor-induced antibodies that blocked T cell recognition of apoB-100, significantly reduced atherosclerosis with a concomitant reduction of macrophage infiltration in the lesions (246). Rutherford et al. observed similar inhibition of T cell activation by oxLDL, but they found that Smase-LDL activated T cells and that the degree of LDL aggregation induced by Smase associated positively with the degree of T cell activation, as measured by the secretion of interleukin-2 (22). Up to 10% of CD4+ T cells isolated from human atherosclerotic plaques displayed specificity for oxLDL (247).

If incubated with whole blood, native and vLDL elicit vastly different T cell activation, native LDL activating CD4+ cells only to a small extent, and vLDL potently activating CD8+ cells (248). The response might be indicative of in vivo formed intimal aggregation of modified LDL.

Distinct roles for different B cell subsets have been reported, anti-oxLDL immunoglobulin IgM antibodies produced by B1 cells being atheroprotective, and anti-oxLDL IgG antibodies produced by B2-cell subsets likely being pro-atherogenic (237, 249, 250). Although only small numbers of B cells are found in atherosclerotic lesions, both IgG and IgM antibodies derived from such cells accumulate in the lesions. Recently, Upadhye et al. identified bone marrow B-1a cells that contribute abundantly to IgM production with a unique IgM pool, which includes anti-monodisaldehyde-modified LDL (MDA-LDL) antibodies. They also showed that expression of the chemokine receptor CXCR4 is a critical factor for the B-1a localization and production of IgM against oxidation-specific epitopes. Expression of CXCR4 on human B-1 cells was greater in humans with low coronary artery plaque burden, suggesting an antiatherogenic function for the cells (251).
Natural IgM vs. IgG
Natural antibodies are antibodies that spontaneously arise without prior infection or defined immune exposure. Most serum antibodies at birth are IgM natural antibodies and, as such, they represent a primitive innate-like “layer” of the adaptive immune system (252, 253). Antigens that are specifically recognized in atherosclerosis include microbial antigens, endogenous heat shock proteins, β-2 glycoprotein I, and modified LDL, especially oxLDL (253). The degree of oxidation of LDL in humans is variable, and two major modifications prepared in vitro—copper-oxidized LDL and MDA-LDL—are recognized by human autoantibodies. Both forms share MDA-lysine as their main oxidation-specific epitope but MDA-LDL contains roughly a 10-fold higher amount of the epitope (254).

IgG and IgM antibodies against oxidation-specific epitopes of oxLDL such as MDA-modified lysine residues or the phosphorylcholine headgroups of oxidized phospholipids have also been found in the plasma, and oxLDL-immune complexes are present in plasma (255) as well as in atherosclerotic lesions of humans and animals (212). Several clinical studies investigated the association of oxLDL autoantibodies with atherosclerosis progression, and in most, atherosclerosis or its progression was directly associated with oxLDL IgG levels, and inversely associated with IgM (256, 257) [reviewed in (240)]. While oxidation-specific epitopes are also commonly found on surfaces of apoptotic cells, microvesicles, and bacteria (195), antibodies against the epitopes were shown to have the capacity to block oxLDL uptake (258), the case for their role in atherogenesis being strong.

Antibodies against carboxamylated LDL have also been found in individuals with uremia or tobacco smoking, and these antibodies also cross-react with MDA- and malondialdehyde acetaldehyde-LDL (259, 260). Further, also IgG against AGE-LDL has been found in human serum and to be associated with diabetes mellitus (261).

LIPID MEDIATORS IN MODIFIED LIPOPROTEINS IMPAIR RESOLUTION
Inflammation is usually followed by its resolution, an active process that reduces leukocyte recruitment, stimulates efferocytosis, repairs tissue damage, and ultimately restores tissue homeostasis. It is partly mediated by proteins such as the anti-inflammatory cytokine IL-10 (119), endogenous gases such as nitric oxide (262), and also by regulatory T cells (263). In recent years, specialized pro-resolving lipid mediators, among others, were discovered to play major roles in mediating the resolution of atherosclerotic lesions [reviewed in (264)]. In the progressing atherosclerotic lesions, efferocytosis of lipid-laden apoptotic cells is impaired, a malfunction that leads to chronic inflammation and a constant influx of circulating monocytes, thus promoting the growth of a necrotic lipid core (263). In macrophage foam cells of atherosclerotic plaques, the lipid mediators, such as 5-lipoxygenase, show nuclear localization, thereby shifting their metabolism to promote the generation of pro-inflammatory leukotrienes and to decrease the production of specialized pro-resolving mediators (265).

OxLDL has been shown to impair efferocytosis in mouse macrophages and to induce apoptosis (266), potentially due to oxidized phospholipids [reviewed in (267)] and cholesterol (268) which are potent mediators of inflammation and influence the ability of the macrophages to perform this function of cell removal. Copper-oxidized LDL was also found to contain lipofuscin-like fluorophores (269), known inducers of the NLRP3-inflammasome (270) and of necroptosis (271). Oleic and linoleic acids associated with E-LDL induced IL-8 expression in ECs (143). Ceramides arising from SMase activity have been shown to inhibit efferocytosis by alveolar macrophages (272, 273). PLA_2-LDL induces the release of arachidonic acid from ECs (147). Arachidonic acid can be converted into prostaglandins, thromboxanes, and leukotrienes, all of which are potent modifiers of inflammation. PLA_2 treatment also releases LPC which is a well-known chemotactic eat-me signal during apoptosis, and which also increases the expression of ICAM-1 and VCAM-1 in ECs and enhances monocyte binding to the endothelium (274). Thus, modified lipoproteins and their cargo directly contribute to impaired resolution in atherogenesis.

DYSFUNCTIONAL HDL
HDLs are considered antiatherogenic [reviewed in (275)]. Firstly, low levels of HDL-C are present in many conditions that are associated with an increased ASCVD risk. The most prominent antiatherogenic property associated with HDL is their ability to induce macrophage cholesterol efflux. HDL also enhances the endothelial synthesis of the vasodilator nitric oxide and thus can also ameliorate endothelial dysfunction. Furthermore, HDL reduces coronary atherosclerosis by decreasing the expression of adhesion molecules on ECs and thereby reducing the infiltration of pro-inflammatory cells and LDL into the subendothelial space. HDL also inhibits lipid oxidation and exerts anti-inflammatory and antiapoptotic actions [reviewed in (275)].

However, oxidative stress can modify HDL. Within the subendothelial space, apoA-I can be oxidized on multiple residues by the proinflammatory enzyme myeloperoxidase (275, 276), and the resulting dysfunctional HDL is associated with an increased incidence of cardiovascular events [reviewed in (218)]. During inflammatory states, inflammatory cytokines induce hepatic expression of the acute-phase serum amyloid A (277) and group IIa sPLA_2 (278), which then leads to the formation of HDL particles that are relatively enriched in SAA, while depleted of apoA-I and phospholipids. Also, increased oxidative stress during inflammation generates dysfunctional HDL that contains oxidatively modified or carboxamylated apoA-I.

HDL remodeling during inflammation also leads to the loss of HDL-associated enzymes such as serum paraoxonase and arylesterases 1 and 3 that normally impede peroxidation of LDL particles; so, the loss of these enzymes decreases the antioxidative and anti-inflammatory capacity of HDL (279).

ApoE-/- mice with dysfunctional HDL displayed an increased cholesterol efflux capacity and lipoprotein peroxidation when
treated with an apoA-I mimetic peptide (280). This peptide has also been able to attenuate LDL aggregation after hydrolysis by SMase provided the peptide was added prior to hydrolysis (184).

Impaired cholesterol efflux capacity of HDL correlates with the severity of atherosclerosis, including the early stages of disease development (281, 282). Thus, cholesterol efflux and resulting foam cell formation can be attributed to the dysfunctional HDL rather than the alterations of circulating levels of normal HDL particles, making dysfunctional HDL a better biomarker of atherosclerosis than the level of HDL-cholesterol (168). Mast cells are present in atherosclerotic lesions where they become activated to secrete heparin-bound neutral proteases capable of degrading apoA-I (283). The mast cell proteases avidly degrade lipid-poor HDL particles and thereby prevent their ability to induce cholesterol efflux from macrophage foam cells, i.e., the first step of reverse cholesterol transport (283). We consider that the HDL-modifying enzymes and agents present in inflamed atherosclerotic lesions are the most critical components of the malfunctioning reverse cholesterol transport system. Accordingly, emerging knowledge and understanding of the various steps of reverse cholesterol transport, particularly of the initiation step when macrophage foam cells and HDL particles interact in an atherosclerotic lesion, is crucially important when attempting to develop novel HDL-targeted therapies (284).

**CLINICAL IMPLICATIONS OF INFLAMMATION INDUCED BY MODIFIED LIPOPROTEINS**

As discussed in this Review, the apoB-containing lipoprotein particles and the lipids contained in them are critical players in atherogenesis. A large and overwhelming body of evidence strengthens the causal role for the cholesterol contained in the LDL particles throughout all stages of atherogenesis (285). Indeed, without cholesterol there is no atherosclerosis. Of particular clinical significance are the clinical observations on lifelong high or low concentrations of LDL-cholesterol (LDL-C). Thus, in patients with familial hypercholesterolemia, the genetic absence of LDL-receptors, which normally remove LDL particles from the circulation, leads to high LDL-C concentrations since birth and inevitably results in accelerated development of coronary atherosclerosis and its clinical sequelae, such as acute myocardial infarction (286). In contrast, individuals with a lifelong history of low LDL-C levels due to genetic defects in the function of the LDL-receptor-suppressing PCSK9 molecule have a dramatic reduction in coronary heart disease even in the presence of other risk factors (287). Finally, the ability of therapeutic lowering of LDL-C has proven the essential role of cholesterol in atherosclerosis and its clinical sequelae (288).

Considering the multitude of inflammatory pathways involved in atherogenesis as discussed here, we wish to add that there is no atherosclerosis without superimposed inflammation in the arterial wall. The contribution of inflammation to the development of atherosclerosis has received support from the findings that statin drugs exert anti-inflammatory effects on atherosclerotic lesions and reduce clinical events due to coronary atherosclerosis, and that part of these beneficial effects may be independent of LDL-C lowering (289). The clinical trials have also demonstrated that many patients remain at increased risk because of persistent elevation in high-sensitivity CRP despite significant reductions in LDL-C level, and that this “residual inflammatory risk” is a viable pharmacologic target of ASCVD (290).

Recent trials have successfully demonstrated the ability of anti-inflammatory interventions to reduce recurrent cardiovascular events even in patients with optimal control of LDL-C level (291). In the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) (292), the pro-inflammatory cytokine IL-1β was inhibited by administering systemically the monoclonal antibody canakinumab to patients after myocardial infarction, and a reduction of recurrent major adverse cardiovascular events was observed (292). Since then, clinical trials testing anti-inflammatory compounds have shown beneficial effects on cardiovascular outcomes. Reduction of cardiovascular events has been observed in several trials involving, in addition to the state-of-the-art lipid-lowering drug regimen, the broad anti-inflammatory drug colchicine. Thus, colchicine was used in the Colchicine Cardiovascular Outcomes Trial (COLCOT) in individuals with a recent myocardial infarction (293), and in the low-dose colchicine trials LoDoCo1 (294) and LoDoCo2 involving individuals with clinically chronic stable coronary disease (295). The pro-inflammatory cytokine IL-6 was targeted by the specific antibody tocilizumab in the ASSessing the effect of Anti-IL-6 treatment in MI (ASSAIL-MI) trial (296, 297), and the treatment attenuated the inflammatory response and the degree of myocardial damage in patients with non-ST-elevation myocardial infarction. Moreover, after acute myocardial infarction hydroxychloroquine reduced the levels of IL-6 at least for a period of 32 months suggesting that this anti-inflammatory drug may reduce cardiovascular events after such an event (298). However, other anti-inflammatory drugs, like the immunosuppressant methotrexate (299) or the p38 mitogen-activated protein kinase (MAPK) inhibitor Losmapimod (300) did not show any effects revealing the specificity of the clinically relevant anti-inflammatory pathways. Of concern are the observations that systemic anti-inflammatory treatments with IL-1β antibodies increased the individual’s susceptibility to fatal infections (301), and that the COLCOT colchicine trial saw a small increase in pneumonia (291).

Interestingly, the adverse effects of air pollutants may occur to a large part via generation of ROS and reactive nitrogen species from organic chemicals present in the inhaled particulate matter (302). Pulmonary oxidative stress and inflammation also results from the activation of pulmonary epithelial cells, macrophages, neutrophils, and ECs by the particulate matter deposited in the lungs. Moreover, the ultrafine particulate matter can reach the systemic circulation where the particles have the potential to directly oxidize HDL or other circulating lipoproteins. Taken together, the pollutants promote the generation of oxLDL, oxHDL, and induce a prothrombotic dysfunction of the coronary endothelium. By causing systemic oxidative stress and
Lipoproteins modified in the intima induce inflammation. Lipoproteins smaller than 80 nm can enter the intima by transcytosis, they get trapped by proteoglycans and during retention they are exposed to enzymes secreted by intimal cells. Modified lipoproteins tend to aggregate, depending on the modification cholesterol crystals can form. Modified lipoproteins also are recognized by antibodies and form immunocomplexes in the intima. The aggregates and crystals can be phagocytized by macrophages or dendritic cells, which can form foam cells or activate T cells, respectively. Mast cells are degranulated during atherogenesis, leading to matrix degradation and lipoprotein degradation. Activated macrophage foam cells secrete more enzymes thus increasing the rate of modification, they secrete cytokines inducing an inflammatory state in the intima, as well as chemoattractants. Endothelial cells either directly by contact with modified lipoproteins or due to pro-inflammatory cytokines from foam cells themselves secrete chemoattractants and increase expression of adhesion molecules, increasing the rate of leukocyte extravasation into the intima. Endothelial activation and dysfunction also lead to a higher rate of lipoproteins entering the intima.

Regarding the development of diabetic vascular injury, the cellular responses to AGEs are thought to largely depend on the interaction between the AGE and AGE-specific cell surface receptors, the RAGEs, which via activation of the transcription factor NF-κB leads to a range of proinflammatory reactions and induction of oxidant stress in the cells involved (304).
Since AGE formation may lead to oxidative stress and oxidative stress may accelerate the formation of specific AGEs, both AGE-LDL and ox-LDL could be involved in the accelerated development of atherosclerosis in patients with type 2 diabetes (305, 306). Based on the above findings, we may postulate that the observations of specific AGEs being associated with the severity of subclinical atherosclerosis and macrovascular complications in patients with long-standing type 2 diabetes, and the requirement of long-standing glucose-lowering (for 10 years) to lower cardiovascular risk, both could at least partly depend on the generation of AGE-LDL in these patients (307, 308). Indeed, among the molecular mechanisms of how hyperglycemia promotes atherosclerosis, the direct protein-modifying effects of glucose appear to be prominent, the glycated LDL particles being both pro-inflammatory and foam cell-forming species of modified lipoproteins (309).

The atherogenic potential of cholesterol in TG-rich lipoprotein particles (TGRls) and their remnants is being increasingly acknowledged (310–313). Indeed, elevated remnant cholesterol associates with increased risk for acute myocardial infarction, ischemic stroke, and, even stronger for peripheral arterial disease, which is also considered to have a strong atherosclerotic component in its pathogenesis (314). The clinical significance of the TGRL remnants has been mostly assigned to their ability to enter the arterial intima and to contribute to the formation of foam cells. However, the mechanisms by which postprandial lipemia induces atherosclerosis also involve induction of endothelial dysfunction, oxidative stress, and inflammation (315). Importantly, the lipoprotein lipo- -mediated hydrolytic modification of the TGRLs takes place not only in capillaries but also in atherosclerosis-susceptible arterial segments where it results in high local concentrations of lipolytic products, such as oxidized free fatty acids which jointly with the TGRLs cause a multitude of inflammatory reactions in the ECs and the cells within the intima (316, 317).

CONCLUDING REMARKS AND FUTURE DIRECTIONS

Modified lipoproteins are the main drivers of atherogenic inflammation of the arterial wall (Figure 3). To decrease the vascular wall inflammation due to modified lipoprotein several concepts are being discussed. Without the entry of cholesterol-containing apoB-lipoproteins into the arterial wall, there is no atherosclerosis. Moreover, it is the current consensus that local inflammation in the evolving atherosclerotic lesions is an inherent part of atherogenesis. Regarding the therapeutic options of atherosclerotic cardiovascular diseases, the lipid-lowering and anti-inflammatory therapies do not compete, but they are complementary and compatible. Currently, a myriad of new treatment options of both dyslipidemia and inflammation in ASCVD is emerging, to mention the availability of RNA-based inhibitors of the hepatic synthesis of apoB-containing lipoproteins which could be administered even once a year (318). Moreover, ASCVD-related events could be substantially reduced by prescription-grade eicosapentaenoic acid in patients with hypertriglyceridemia (319). In that study, the beneficial effect likely at least to some extent resulted from lowering cholesterol accumulation and reduction of inflammation in the arterial wall via changes in composition of lipoproteins and cells.

Finally, the perception that inflammation would replace traditional risk factors of atherosclerosis poses a false dichotomy (320). Currently, lowering the concentration of the apoB-containing lipoproteins and their remnants either by dietary or pharmacological means is the mainstream approach to combat atherosclerosis both in the primary and secondary prevention settings, while the anti-inflammatory therapies serve as adjunct therapies in the setting of secondary prevention strategies. This chronology adopts our traditional understanding of cholesterol accumulation being the primary event and an inflammatory reaction being a secondary event taking place in the arterial intima, the concept originating in the early work dealing with animal models of atherosclerosis. This basic concept is also reflected in the present-day clinical approach in which the inflammation is considered to present a residual cardiovascular risk after very efficient lowering of LDL-C in patients with clinically manifest ASCVD (321). However, as discussed in this review in-depth, we may consider the cholesterol- and TG-containing lipoproteins entering the arterial intima as innocent bystanders, who are attacked by the “healthy” resident macrophages which have been present in the intima lifelong, and which are performing their physiological patrol tasks in this tissue like they do in any tissue (322). Then, it is, after all the close encounter of the two which ignites and sustains the atherogenic process in which cholesterol accumulation and inflammation coexist. This novel understanding is necessary when aiming at developing new anti-atherosclerotic therapies aiming at primary prevention of ASCVD, as it dictates that the inflammatory component is not only a residual risk but a risk existing throughout the development of atherosclerosis. Recent results obtained in mice with early atherosclerosis revealed that inhibition of IL-1β and NLRP3 inflammasome reduces leukocyte accumulation in atherosclerotic aortas (323). Thus, we may predict that cardiovascular interventions utilizing lowering the levels of circulating apoB-containing lipoproteins, prevention of their modifications, and reduction of the numbers of lesional macrophages already at an initial or early stage of the long subclinical asymptomatic phase of atherosclerosis may ultimately provide us the tools required for full eradication of the clinically manifest ASCVD.

AUTHOR CONTRIBUTIONS

ML, KÖ, and PK designed, wrote, and edited the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

Wihuri Research Institute was maintained by the Jenny and Antti Wihuri Foundation. This study was also supported by grants from the Academy of Finland (#332564), Novo Nordisk Fonden (#NNF19OC0057411), the Finnish Foundation for Cardiovascular Research, and the Aarne Koskelo Foundation.
room to prove the causation? Curr Cardiol Rev. (2020) 16:3-10. doi: 10.2174/1573403315666190531111932

39. Epps KC, Willensky RL. Lp-PLA2: a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med. (2011) 269:94–106. doi: 10.1111/j.1365-2796.2010.02390.x

40. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochimica et Biophysica Acta (BBA) Mol Cell Biol Lipids. (2009) 1791:327–38. doi: 10.1016/j.bbalip.2009.02.015

41. Kolodgie FD, Burke AP, Skorja KS, Ladich E, Kutrys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. (2006) 26:2523-9. doi: 10.1161/ATV.0000000000000177

42. Rosengren B, Peliot H, Umaerus M, Jonsson-Rylander AC, Mattsson-Hultén L, Hallberg C, et al. Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet. Arterioscler Thromb Vasc Biol. (2006) 26:1579-85. doi: 10.1161/01.ATV.0000221231.56617.e7

43. Yamamoto K, Isogai Y, Sato H, Taketomi Y, Murakami M. Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerotic integration with lipodomics. Anal Bioanal Chem. (2011) 400:1829-42. doi: 10.1007/s00216-011-4864-2

44. Öörni K, Hakala JK, Annila A, Ala-Korpela M, Kovanen PT. Phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that hydrolyze LDL hydrolytic products and are more atherogenic at acidic pH. Artherosclerosis. (2009) 207:352-9. doi: 10.1016/j.atherosclerosis.2009.04.031

45. Duewell P, Sirois CM, Vladimer G, Bauernfeind FG, et al. Phospholipase A2-modified LDL particles retain the generated hydrolytic products and are more atherogenic at acidic pH. Blood Rev. (2010) 24:260-7. doi: 10.1016/j.blre.2010.09.001

46. Wieland E, Dorweiler B, Bonitz U, Lieser S, Walev I, Bhakdi S. Complement system: ancient interactions between components of innate immunity. Mol Sci. (2006) 26:2523-9. doi: 10.3390/mcs26090526

47. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease. Nature. (2010) 464:1357–61. doi: 10.1038/nature08938

48. Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory diseases. Immune Netw. (2018) 18:e27. doi: 10.4103/in.2018.18.e27

49. Kim H, Conway EM. Platelets and complement cross-talk in early atherosogenesis. Front Cardiovasc Med. (2019) 6:131. doi: 10.3389/fcvm.2019.00131

50. Oksjoki R, Kovanen PT, Pentikäinen MO. Role of complement activation in atherosclerosis. Curr Opin Lipidol. (2003) 14:477-82. doi: 10.1097/00001079-200301000-00008

51. Martin-Ventura JL, Martinez-Delo P, Roldán-Montero R, Gomez-Guerrero C, Blanco-Colio LM. Role of complement system in pathological remodeling of the vascular wall. Mol Immunol. (2011) 48:267-15. doi: 10.1016/j.molimm.2011.09.016

52. Oksjoki R, Kovanen PT, Meri S, Pentikäinen MO. Function and regulation of the complement system in cardiovascular diseases. Front Biosci. (2007) 12:4696-708. doi: 10.2741/2419

53. Baines AC, Brodsky RA. Complementopathies. Blood Rev. (2017) 31:213-23. doi: 10.1016/j.ble.2017.02.003

54. Elieh Ali Komi D, Shafigat F, Kovanen PT, Meri S. Mast cells and complement system: ancient interactions between components of innate immunity. Arterioscler Thromb Vasc Biol. (2020) 40:2581-8. doi: 10.1161/ATV.0000000000001413

55. Torzewski M. Enzymatically modified LDL, atherosclerosis and beyond: paving the way to acceptance. Front Biosci. (2018) 23:1257-71. doi: 10.2741/4642

56. Arlaud GJ, Biro A, Ling WL. Enzymatically modified low-density lipoprotein is recognized by c4q and activates the classical complement pathway. J Lipids. (2011) 2011:376092. doi: 10.1155/2011/376092

57. Torzewski M. The initial human atherosclerotic lesion and lipoprotein modification—a deep connection. Int J Mol Sci. (2021) 22:11488. doi: 10.3390/ijms22111488

58. Allahverdian S, Chehroudi AC, McManus BM, Abraham T, Francis GA. Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Circulation. (2014) 129:1531-9. doi: 10.1161/CIRCULATIONAHA.113.005015

59. Pryma CS, Ortega C, Dubland JA, Francis GA. Pathways of smooth muscle foam cell formation in atherosclerosis. Curr Opin Lipidol. (2019) 30:117-24. doi: 10.1097/MOL.0000000000000574

60. Mineo C. Lipoprotein receptor signalling in atherosclerosis. Cardiovasc Res. (2020) 116:1254-74. doi: 10.1093/cvr/cvz338

61. Lopes-Virella MF, Binzafar N, Takei A, La Via M, Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis. (1997) 135:161-70. doi: 10.1016/s0021-9150(97)00157-3

62. Kruth HS. Sequestration of aggregated low-density lipoproteins by macrophages. Curr Opin Lipidol. (2002) 13:485-8. doi: 10.1097/00001433-200210000-00003

63. Rajamäki K, Lappalainen J, Öörni K, Välimäki E, Matikainen S, Kovanen PT, et al. Cholesterol crystals activate the NLRP3

64. Baba S, Kovanen PT, Takai Y, Kimura M, Kishida K, Kishida K, et al. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta (BBA) Mol Cell Biol Lipids. (2009) 1791:327–38. doi: 10.1016/j.bbalip.2009.02.015

65. Leht J, Soininen I, Peränen J, Parvinen J, Soininen I, Peränen J, et al. Alternative C3 complement system: lipids and atherosclerosis. Int J Mol Sci. (2021) 22:5122. doi: 10.3390/ijms22105122

66. Oksjoki R, Kovanen PT, Pentikäinen MO. Role of complement activation in atherosclerosis. Curr Opin Lipidol. (2003) 14:477-82. doi: 10.1097/00001079-200301000-00008

67. Mineo C. Lipoprotein receptor signalling in atherosclerosis. Cardiovasc Res. (2020) 116:1254-74. doi: 10.1093/cvr/cvz338

68. Lopes-Virella MF, Binzafar N, Takei A, La Via M, Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis. (1997) 135:161-70. doi: 10.1016/s0021-9150(97)00157-3

69. Kruth HS. Sequestration of aggregated low-density lipoproteins by macrophages. Curr Opin Lipidol. (2002) 13:485-8. doi: 10.1097/00001433-200210000-00003
inflammations in human macrophages: a novel link between cholesterol metabolism and inflammation. *PLoS ONE.* (2010) 5:e11765. doi: 10.1371/journal.pone.0011765

76. Oörni K, Lehti S, Sjövall P, Kovanen PT. Triglyceride-rich lipoproteins as a source of proinflammatory lipids in the arterial wall. *Curr Med Chem.* (2018) 25:1-10. doi: 10.2174/0929867325666180300504819

77. Haka AS, Grosheva I, Chiang E, Buxbaum AR, Raidt BA, Pierini LM, et al. Macrophages create an acidic extracellular hydrolytic compartment to digest aggregated lipoproteins. (2009) 20:4932-40. doi: 10.1091/mcb.e07-0559

78. Haka AS, Singh RK, Grosheva I, Hoffner H, Capetillo-Zarate E, Chin HF, et al. Monocyte-derived dendritic cells upregulate extracellular catabolism of aggregated low-density lipoprotein on maturation, leading to foam cell formationsignificance. (2015) 35:2092-103. doi: 10.1161/ATVBAHA.115.305843

79. Singh RK, Barbosa-Lorenzi VC, Lund FW, Grosheva I, Maxfield FR, Haka AS. Degradation of aggregated LDL occurs in complex extracellular sub-compartments of the lysosomal synapse. (2016) 129:1072-82. doi: 10.1242/jcs.181743

80. Grosheva I, Haka AS, Qin C, Pierini LM, Maxfield FR. Aggregated LDL in contact with macrophages induces local increases in free cholesterol levels that regulate local actin polymerization. *Arterioscler Thromb Vasc Biol.* (2009) 29:1615-21. doi: 10.1161/ATVBAHA.109.191882

81. Singh RK, Haka AS, Asmal A, Barbosa-Lorenzi VC, Grosheva I, Chin HF, et al. TLR4 (toll-like receptor 4)-dependent signaling drives extracellular catabolism of LDL (low-density lipoprotein) aggregates. *Arterioscler Thromb Vasc Biol.* (2020) 40:886-102. doi: 10.1161/ATVBAHA.119.313200

82. Oörni K, Rajamakri K, Nguyen SD, Lihdesmäki K, Pihlarii R, Lee-Rueckert M, et al. Acidification of the intimal fluid: the perfect storm for atherogenesis. *J Lipid Res.* (2015) 56:203-14. doi: 10.1194/jlr.R050252

83. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. *Annu Rev Biochem.* (1983) 52:223-61. doi: 10.1146/annurev.bi.52.070183.001255

84. Ahmad F, Leake DS. Lysosomal oxidation of LDL alters lysosomal pH, induces senescence, and increases secretion of pro-inflammatory cytokines in human macrophages. *J Lipid Res.* (2019) 60:998-110. doi: 10.1194/jlr.M088245

85. Ahmad F, Mitchell RD, Houben T, Palo A, Yadati T, Parnell AJ, et al. Cysteine decreases low-density lipoprotein oxidation, causes regression of atherosclerosis, and improves liver and muscle function in low-density lipoprotein receptor-deficient mice. *J Am Heart Assoc.* (2021) 10:017524. doi: 10.1161/JAHA.120.017524

86. Yancey PG, Jerome WG. Lysosomal sequestration of free and oxidized lipoproteins. *Arterioscler Thromb Vasc Biol.* (2009) 29:1615-21. doi: 10.1161/ATVBAHA.109.191882

87. Brown AJ, Mander EL, Gelissen IC, Kritharides L, Dean RT, Jessup M, et al. Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. *Am J Pathol.* (2007) 170:416-26. doi: 10.1016/j.ajpath.2007.06.0400

88. Nissilä E, Hakala P, Leskinen K, Roig A, Syed S, Van Kessel KPM, et al. Complement factor H and apolipoprotein E participate in regulation of inflammation in THP-1 macrophages. *Front Immunol.* (2018) 9:2701. doi: 10.3389/fimmu.2018.02701

89. Miller YI, Choi SH, Fang L, Tsimikas S. Lipoprotein modification and macroage uptake: role of pathologic cholesterol transport in atherogenesis. *Subcell Biochem.* (2010) 51:229-51. doi: 10.1007/978-90-481-8622-8_8

90. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. *Nat Rev Cardiol.* (2009) 6:399-409. doi: 10.1038/nrcardi.2009.55

91. Xu S, Ogura S, Chen J, Little PJ, Moss J, Liu P. LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. *Cell Mol Life Sci.* (2013) 70:2859-72. doi: 10.1007/s00018-011-1194-z

92. Murray PJ. Macrophage polarization. *Annu Rev Physiol.* (2017) 79:541-66. doi: 10.1146/annurev-physiol-022516-034339

93. Tabas I, Bornfeldt KE. Intracellular and intercellular aspects of macrophage immunometabolism in atherosclerosis. *Circ Res.* (2020) 126:1209-27. doi: 10.1161/CIRCRESAHA.119.315939

94. Rigamonti E, Chinetti-Gbaguidi G, Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXR receptors in mice and men. *Arterioscler Thromb Vasc Biol.* (2008) 28:1050-9. doi: 10.1161/ATVBAHA.107.138998

95. Hudson BI, Lippman ME. Targeting RAGE signaling in inflammatory disease. *Annu Rev Med.* (2018) 69:349-64. doi: 10.1146/annurev-med-041316-085215

96. Goulouloupou S, McCarthy CG, Webb RC. Toll-like receptors in the vascular system: sensing the dangers within. *Pharmacol Rev.* (2016) 68:142-67. doi: 10.1124/pr.114.010090

97. Guo H, Callaway JB, Ting JPY. Inflammomas: mechanism of action, role in disease, and therapeutics. *Nat Med.* (2015) 21:677-87. doi: 10.1038/nm.3893

98. Grebe A, Hoss F, Latz E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. *Circ Res.* (2018) 122:1722-40. doi: 10.1161/CIRCRESAHA.118.311362

99. He X, Fan X, Bai B, Lu N, Zhang S, Zhang L. Pyroptosis is a critical immune-inflammatory response involved in atherosclerosis. *Pharmacol Res.* (2021) 165:105447. doi: 10.1016/j.phrs.2021.105447

100. Orekhov AN, Oishi Y, Nikiforov NG, Zhelankin AV, Dubrovsky L, Sobenin IA, et al. Modified LDL particles activate inflammatory pathways in monocye-derived macrophages: transcriptome analysis. *Carr Pharmaceut Design.* (2018) 24:3135-41. doi: 10.2174/18161282466180911120039

101. Vroman A, Ruvkun V, Shvarts E, Wojtkiewicz G, Santos Masson G, Tesmenitsky Y, et al. Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis. *Eur Heart J.* (2019) 40:2482-91. doi: 10.1093/eurheartj/ech2008
112. Ridker PM. Anticytokine agents: targeting interleukin signaling pathways for the treatment of atherothrombosis. Circ Res. (2019) 124:437-50. doi: 10.1161/CIRCRESAHA.118.313129

113. Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol. (2021) 18:58-68. doi: 10.1038/s41574-020-0431-7

114. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. (2006) 8 (Suppl 2):S3. doi: 10.1186/ar1917

115. Toussoulis D, Okononou E, Economidou E, Crea F, Kaski JC. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J. (2016) 37:1723-32. doi: 10.1093/eurheartj/ehv759

116. McKellar GE, Carey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol. (2009) 6:410-7. doi: 10.1038/nrcardio.2009.57

117. An Z, Li J, Yu J, Wang X, Gao H, Zhang W, et al. Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-kB signaling in macrophages. Cell Cycle. (2019) 18:2928-38. doi: 10.1080/15384101.2019.1662678

118. Apostolakis S, Vogiatzi K, Amanatidou V, Spandidos DA. Interleukin 8 and cardiovascular disease. Cardiovasc Res. (2009) 84:353-60. doi: 10.1093/cvr/cxp241

119. Han X, Boisvert WA. Interleukin-10 protects against atherosclerosis by modulating multiple atherogenic macrophage function. Thromb Haemost. (2015) 113:503-12. doi: 10.1160/TH14-06-0509

120. Ye J, Wang Y, Wang Z, Liu L, Yang Z, Wang M, et al. Roles and mechanisms of interleukin-12 family members in cardiovascular diseases: opportunities and challenges. Front Pharmacol. (2020) 11:129. doi: 10.3389/fphar.2020.001129

121. Elyasi A, Voloshyna I, Ahmed S, Kasselman LJ, Behbodikhah J, De Leon I, et al. The role of interferon-γ in cardiovascular disease: an update. Inflamm Res. (2020) 69:975-88. doi: 10.1007/s00011-020-01382-6

122. van der Vorst EPC, Döring Y, Weber C. Chemokines and their receptors in atherosclerosis. J Mol Med. (2015) 93:963-71. doi: 10.1007/s00109-015-1317-8

123. Hamilton JA, Cook AD, Tak PP. Anti-colony-stimulating factor therapies and fibrosis in atherosclerosis. Arterioscler Thromb Vasc Biol. (2012) 32:1653-70. doi: 10.1161/ATVBAHA.111.231631

124. Tabas I, Bornfeldt KE. Macrophage phenotype and function in different stages of atherosclerosis. Circ Res. (2016) 118:653-67. doi: 10.1161/CIRCRESAHA.115.306256

125. Chen P-Y, Qin L, Li G, Wang Z, Dahlman JE, Malagon-Lopez J, Toma I, McCaffrey TA. Transforming growth factor-β modulates cytokine production, cholesterol efflux and CD11c expression in rheumatoid arthritis patients. J Intern Med. (2012) 269:2504-9. doi: 10.1111/j.1365-2966.2012.05799.x

126. Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized LDL, mediates mononuclear leukocyte adhesion. Atherosclerosis. (2007) 192:56-66. doi: 10.1016/j.atherosclerosis.2006.06.012

127. Klouche M, Gottschling S, Gerl V, Hell W, Husmann M. Enzymatically modified, nonoxidized LDL induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion. Atherosclerosis. (2006) 193:161-71. doi: 10.1016/j.atherosclerosis.2006.07.024
of adhesion molecules: role of LOX-1. Circ Res. (2001) 89:1155-60. 
doi: 10.1161/hc401.100598

150. Norata GD, Pirillo A, Callegari E, Hamsten A, Catapano AL, Eriksson P. Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. Cardiovasc Res. (2003) 59:169-80. doi: 10.1016/S0008-6363(03)00335-3

151. Wang GP, Deng ZD, Ni J, Qu ZL. Oxidized low density lipoprotein and very low density lipoprotein enhance expression of monocyte chemotactant protein-1 in rabbit peritoneal exudate macrophages. Atherosclerosis. (1997) 133:31-6. doi: 10.1016/S0952-8132(97)00109-3

152. Wang G, Deng Z, Ni J. Expression of monocyte chemotactant protein-1 in monocytes and effects of native and oxidized very low density lipoproteins. J Tengji Med Univ. (1997) 17:203-5. doi: 10.1007/BF02895619

153. Apostolov EO, Shah SV, Ok E, Basnakian AG. Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol. (2007) 27:826-32. doi: 10.1161/01.ATV.0000287895.75112.8a

154. Chen Z, Ding S, Wang YP, Chen L, Mao YJ, Yang Y, et al. Association of carbamylated high-density lipoprotein with coronary artery disease in type 2 diabetes mellitus: carbamylated high-density lipoprotein of patients promotes monocyte adhesion. J Transl Med. (2020) 18:460. doi: 10.1186/s12967-020-02623-2

155. Toma L, Stancu CS, Sima AV. Endothelial dysfunction in diabetes is aggravated by glycated lipoproteins: novel molecular therapies. Biomedicines. (2020) 8:918. doi: 10.3390/biomedicines8010018

156. Khan BV, Parthasarathy S, Alexander RW, Medford RM. Modified low density lipoprotein enhances expression of monocyte chemoattractant protein-1 gene expression in human vascular endothelial cells. J Clin Invest. (1995) 95:1262-70. doi: 10.1172/JCI117776

157. Zhao R, Ren S, Moghadamshahin M, Rempel JD, Shen GX. Involvement of fibroinolytic regulators in adhesion of monocytes to vascular endothelial cells induced by glycated LDL and to aorta from diabetic mice. J Leukocyte Biol. (2014) 95:941-9. doi: 10.1189/jlb.ol512326

158. Hedgkinson CP, Laxton RC, Patel K, Ye S. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway: implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol. (2008) 28:2275-81. doi: 10.1161/ATVBAHA.108.175992

159. Isoda K, Folco E, Marwali MR, Ohsuzu F, Libby P. Glycated LDL by cultured human coronary artery endothelial cells. J Cell Biol. (2003) 162:463-71. doi: 10.1083/jcb.200205119

160. Toma L, Stancu CS, Botez GM, Sima AV, Simionescu M. Irreversibly glycated LDL induces oxidative stress and accelerated senescence in human endothelial progenitor cells. FASEB J. (2011) 25:1314-22. doi: 10.1096/fj.10-173377

161. Verbrugge FH, Tang WHZ, Hazen SL. Protein carbamylation and cardiovascular disease. Kidney Int. (2015) 88:474-8. doi: 10.1038/ki.2015.166

162. Beis SE, Olson MB, Fried L, Reeser V, Mankad S, Pepine CJ, et al. Mild renal insufficiency is associated with angiographic coronary artery disease in women. Circulation. (2002) 105:2826-9. doi: 10.1161/01.CIR.0000021597.63026.65

163. Speer T, Owala FO, Holy EW, Zewinger S, Frenzel FL, Stahle BE, et al. Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur Heart J. (2014) 35:3021-32. doi: 10.1093/eurheartj/ehu11

164. Carracedo J, Merino A, Bricerio C, Soriano S, Buendia P, Calleros L, et al. Carbamylated low-density lipoprotein induces oxidative stress and accelerated senescence in human endothelial progenitor cells. FASEB J. (2011) 25:1314-22. doi: 10.1096/fj.10-173377

165. Apostolov EO, Ok E, Burns S, Nawaz S, Savenka A, Shah S, et al. Carbamylated-oxidized LDL: proatherosclerotic effects on endothelial cells and macrophages. J Atheroscler Thromb. (2013) 20:3878-92. doi: 10.5551/jat.14035

166. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA. (1994) 91:9441-5. doi: 10.1073/pnas.91.20.9441

167. Artwohl M, Graier WE, Roden M, Bischof M, Freudenthaler A, Waldhaeusl W, et al. Diabetic LDL triggers apoptosis in vascular endothelial cells. Diabetes. (2003) 52:1240-7. doi: 10.2373/diabetes.52.5.1240

168. Gira S, Mauoche S, Atout R, Hanwerdker K, Lambou G, Cambien F, et al. Phospholipolyzed LDL induces an inflammatory response in endothelial cells through endoplasmic reticulum stress signaling. FASEB J. (2010) 24:3248-97. doi: 10.1096/fj.09-146852

169. Nguyen SD, Korhenen EA, Lorye MB, Hakanpää L, Mäyränpää MI, Kovanen PT, et al. Lysosphophatidylcholine in phospholipase A(2)-modified LDL triggers secretion of angiopoietin 2. Atherosclerosis. (2021) 327:87-99. doi: 10.1016/j.atherosclerosis.2021.04.007

170. Lauber K, Bohn E, Kröber SM, Xiao YJ, Blumenthal SG, Lindemann AN. Modification of LDL with human secretory phospholipase A2 (sPLA2-I) reduces triglyceride accumulation in macrophages. J Lipid Res. (2013) 54:87-99. doi: 10.1194/jlr.M031510-JLR200
186. Kolesnik R, Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene. (2003) 22:5897-906. doi: 10.1088/sj. onc.1206702

187. Summers BA, Chaurasia B, Holland WL. Metabolic messengers: ceramides. Nat Metab. (2019) 1:1051-8. doi: 10.1038/s42255-019-0134-8

188. Kinscherf R, Claus R, Deigner HP, Nauen O, Geluke C, Hermetter A, et al. Modified low density lipoprotein delivers substrate for ceramide formation and stimulates the sphingomyelin-ceramide pathway in human macrophages. FEBs Lett. (1997) 405:55-9. doi: 10.1016/S0014-5793(97)00157-9

189. Chellan B, Reardon CA, Getz GS, Hofmann Bowman MA. Enzymatically modified low-density lipoprotein promotes foam cell formation in smooth muscle cells via macroinocytosis and enhances receptor-mediated uptake of oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol. (2016) 36:1101-13. doi: 10.1161/ATVBAHA.116.307306

190. Li F, Zhang H. Lysosomal acid lipase in lipid metabolism and beyond. Arterioscler Thromb Vasc Biol. (2019) 39:850-6. doi: 10.1161/ATVBAHA.119.312136

191. Heltiana C, Robciuc A, Botez G, Musina C, Stancu C, Sima AV, et al. Modified low density lipoproteins decrease the activity and expression of lysosomal acid lipase in human endothelial and smooth muscle cells. Cell Biochem Biophys. (2011) 61:209-16. doi: 10.1007/s12013-011-9190-8

192. Ismael FO, Barrett TJ, Sheikhour D, Brown BE, Davies MJ, Hawkins CL. Role of myeloperoxidase oxidants in the modulation of cellular lysosomal enzyme function: a contributing factor to macrophage dysfunction in atherosclerosis? J Pathol. (2016) 234:218-23. doi: 10.1002/typ.22183

193. Zhang H. Lysosomal acid lipase and lipid metabolism: new mechanisms, new questions, and new therapies. Curr Opin Lipidol. (2018) 29:218-23. doi: 10.1097/MOL.0000000000000507

194. den Hartigh LJ, Altman R, Norman JE, Rutledge JC. Postprandial VL DL lipolysis products increase monocyte adhesion and lipid droplet formation via activation of ERK2 and NFκB. FEBS Lett. (2014) 580:109-20. doi: 10.1111/1742-4658.12557

195. Binder CJ, Papac-Milicevic N, Witztum JL. Innate sensing of oxidation-modified low density lipoprotein promotes foam cell formation in smooth muscle cells in atherosclerosis. J Leukoc Biol. (1995) 57:427-33. doi: 10.1002/jlb.57.3.427

196. Nurmi K, Niemi K, Kareinen I, Silventoinen K, Lorye MB, Chen Y, et al. Native and oxidised lipoproteins negatively regulate the serum amyloid A-induced NLRP3 inflammasome activation in human macrophages. Clin Transl Immunol. (2021) 10:e1323. doi: 10.1002/cit2.1323

204. Orr AW, Hastings NE, Blackman MR, Warnhoff BR. Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J Vasc Res. (2010) 47:168-80. doi: 10.1159/000330095

205. Lin J, Shou X, Mao X, Dong J, Mohabber N, Kushwaha KK, et al. Oxidized low density lipoprotein induced caspase-1 mediated pyroptotic cell death in macrophages: implication in lesion instability? PLoS ONE. (2013) 8:e62148. doi: 10.1371/journal.pone.0062148

206. Zhaolin Z, Jiaojiao C, Peng W, Yami L, Tingting Z, Jun T, et al. OxLDL induces vascular endothelial cell pyroptosis through mir-125a-5p/TET2 pathway. J Cell Physiol. (2019) 234:7475-91. doi: 10.1002/jcp.27509

207. Ajoilabadly A, Askhodapasandhokmahab H, Libby P, Tuomilehto J, Lip GYH, Penninger JM, et al. Ferritinophagy and ferroptosis in the management of metabolic diseases. Trends Endocrinol Metab. (2021) 32:444- 62. doi: 10.1016/j.tendm.2021.04.010

208. Conrad M, Pratt DA. The chemical basis of ferroptosis. Nat Chem Biol. (2019) 15:1137-47. doi: 10.1038/s41558-019-0408-1

209. Bai T, Li M, Liu Y, Qiao Z, Wang Z. Inhibition of ferroptosis alleviates atherosclerosis through attenuating lipid peroxidation and endothelial dysfunction in mouse aortic endothelial cell. Free Radical Biol Med. (2020) 160:92-102. doi: 10.1016/j.freeradbiomed.2020.07.026

210. Yang K, Song H, Yin D. PDSS2 inhibits the ferroptosis of vascular endothelial cells in atherosclerosis by activating Nrf2. J Cardiovasc Pharmacol. (2021) 77:767-76. doi: 10.1097/FJC.000000000001030

211. Rhoads JP, Lukens JR, Wilhelm AJ, Moore JL, Mendez-Fernandez Y, Kanneganti T-D, et al. Oxidized low-density lipoprotein immune complex priming of the Nlrp3 inflammasome involves TLR and FcγR cooperation and is dependent on CARD9. J Immunol. (2017) 198:2105-14. doi: 10.4049/jimmunol.1601563

212. Yli-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. (1994) 14:32-40. doi: 10.1161/01.ATV.14.1.32

213. Lappalainen J, Lindstedt KA, Oskoki R, Kovanen PT. OxLDL-IgG immune complexes induce expression and secretion of proatherogenic cytokines by cultured human mast cells. Atherosclerosis. (2011) 214:357-63. doi: 10.1016/j.atherosclerosis.2010.11.024

214. Kovanen PT. Mast cells as potential accelerators of human atherosclerosis-from early to late lesions. Int J Mol Sci. (2019) 20:4479. doi: 10.3390/ijms20184479

215. Zhao R, Ma X, Shen GX. Transcriptional regulation of plasminogen activator inhibitor-1 in vascular endothelial cells induced by oxidized very low density lipoproteins. Mol Cell Biochem. (2008) 317:197-204. doi: 10.1007/s11010-008-9851-0

216. Au-Yeung KK, Ok, Choy PC, Zhu DY, Siow YL. Magnesium tanshinone inhibits the ferroptosis of vascular endothelial cells in atherosclerosis by activating Nrf2. J Vasc Res. (2021) 58:1053-62. doi: 10.1016/j.jvr.2020.12.007

217. Argmann CA, Van Den Diepstraten CH, Sawyez CG, Edwards JY, Vrancken PE, Hegele RA, Wolfe BM, et al. Transforming growth factor-bet1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler Thromb Vasc Biol. (2001) 21:20118. doi: 10.1161/01.ATV.14.1.32

218. Itabe H, Sawada N, Makiyama T, Obama T. Structure and dynamics of oxidized lipoproteins in vivo: roles of high-density lipoprotein. Biochim. (2021) 9:665. doi: 10.3390/biom9060655

219. Perez L, Valletos A, Echeverria C, Varela D, Cabello-Verrugio C, Simon F. OxHDLC controls LC3-I expression and plasma membrane localization through a mechanism dependent on NOX/ROS/NFκB pathway on endothelial cells. Lab Invest. (2019) 99:421-37. doi: 10.1038/s41374-018-0151-3

220. Ren J, Jin W, Chen H. oxHDLC decreases the expression of CD36 on human macrophages through PPARgamma and p38 MAP kinase dependent mechanisms. Mol Cell Biochem. (2010) 342:171-81. doi: 10.1007/s11010-010-0481-y

221. Kuwert T, Composto VV, Febrario M, Podrez EA, Moore KJ, Anderson L, Koehn S, et al. Scavenger receptors class A/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. (2002) 277:49982-8. doi: 10.1074/jbc.M29694200
224. Assinger A, Koller F, Schmid W, Zellner M, Babeluk R, Koller E, et al. Specific binding of hypochlorite-oxidized HDL to platelet CD36 triggers proinflammatory and procoagulant effects. Atherosclerosis. (2010) 212:153-60. doi: 10.1016/j.atherosclerosis.2010.05.010

225. Kapoor S, Opneja A, Nayak L. The role of neutrophils in thrombosis. Thromb Res. (2018) 170:87-96. doi: 10.1016/j.thromres.2018.08.005

226. Döring Y, Libby P, Soehnlein O. Neutrophil extracellular traps participate in cardiovascular diseases: recent experimental and clinical insights. Circ Res. (2020) 126:1228-41. doi: 10.1161/CIRCRESAHA.120.315931

227. Castanheira FVS, Kubes P. Neutrophils and NETs in modulating acute and chronic inflammation. Blood. (2019) 133:2178-85. doi: 10.1182/blood-2018-11-844530

228. Dolgova A, Hermsmeyer A, Strodthoff D, Wurm M, Hansson EM, Nicoletti A, et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med. (2010) 207:1081-93. doi: 10.1084/jem.20092243

229. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci. (1995) 92:3893-7. doi: 10.1073/pnas.92.9.3893

230. Kyaw T, Winship A, Tay C, Kanellakis P, Hosseini H, Cao A, et al. Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apo-deficient mice. Circulation. (2013) 127:1028-39. doi: 10.1161/CIRCULATIONAHA.112.01347

231. Assinger A, Ketelhuth DF, Strodthoff D, Wurm M, Hansson EM, Nicoletti A, et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med. (2010) 207:1081-93. doi: 10.1084/jem.20092243

232. Zardawi F, Gul S, Abdulkareem A, Sha A, Yates J. Association between oxidized low-density lipoproteins and cardiovascular disease: the role of neutrophils. Atherosclerosis. (2009) 197:366-75. doi: 10.1016/j.atherosclerosis.2009.03.049

233. Binder CJ, Silverman GJ. Natural antibodies and the autoimmunity in atherosclerosis. Circ Res. (2013) 114:1640-60. doi: 10.1161/CIRCRESAHA.114.302761

234. Virella G, Wilson K, Elkes J, Hammad SM, Rajab HA, Li Y, et al. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and carbohydrate moieties of the lipoprotein. J Biol Chem. (2000) 275:9163-9. doi: 10.1074/jbc.M000361-1JL200

235. Vermillion J, Hermsmeyer A, Strodthoff D, Wurm M, Hansson EM, Nicoletti A, et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med. (2010) 207:1081-93. doi: 10.1084/jem.20092243
297. Kleveland O, Kunstg G, Bratlie M, Ueland T, Broch K, Holte E, et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. *Eur Heart J*. (2016) 37:2406-13. doi: 10.1093/eurheartj/ehw171

298. Ulander L, Tolppanen H, Hartman O, Rissanen TT, Paakkonen R, Kuusisto J, et al. Hydroxycarbamine induces interleukin-6 levels after myocardial infarction: the randomized, double-blind, placebo-controlled OXIL pilot trial. *Int J Cardiol*. (2021) 337:21-7. doi: 10.1016/j.ijcard.2021.04.062

299. Ridker PM, Everett BM, Pradhan A, Zhang J, Gaziano JM, Solomon DH, Vasan RS, et al. Modified Lipoproteins Induce Inflammation. *N Engl J Med*. (2019) 380:752-62. doi: 10.1056/NEJMoa1809798

300. O’Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, et al. Effect of losaparin on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial. *JAMA*. (2016) 315:1591-9. doi: 10.1001/jama.2016.3609

301. Baylis RA, Gomez D, Mallat Z, Pasterkamp G, Owens GK. The CANTOS trial: one important step for clinical cardiology but a giant leap for vascular biology. *Arterioscler Thromb Vasc Biol*. (2017) 37:e174-7. doi: 10.1161/ATVBAHA.117.310997

302. Delfino RJ, Staimer N, Vaziri ND. Air pollution and circulating biomarkers of oxidative stress. *Air Qual Atmos Health*. (2011) 4:37-52. doi: 10.1007/s11869-010-0095-2

303. Ukena C, Mahfoud F, Kindermann M, Kindermann I, Bals R, Voors AA, et al. The cardiopulmonary continuum systemic inflammation as “common soil” of heart and lung disease. *Int J Cardiol*. (2010) 145:172-6. doi: 10.1016/j.ijcard.2010.04.082

304. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, et al. RAG E: a novel cellular receptor for advanced glycation end products. *Diabetes*. (1996) 45(Suppl 3):S77-80. doi: 10.2337/db95.3.577

305. Vlassara H. Advanced glycation end-products and atherosclerosis. *Ann Med*. (1996) 28:419-26. doi: 10.3109/07853899608999102

306. Goldin A, Beckman JA, Schmidt AM, Greager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. *Circulation*. (2006) 114:597-605. doi: 10.1161/CIRCULATIONAHA.106.621854

307. Koska J, Saremi A, Howell S, Bahn G, De Courten B, Ginsberg HN, et al. Advanced glycation end products, oxidation products, and incident cardiovascular events in patients with type 2 diabetes. *Diabetes Care*. (2018) 41:570-6. doi: 10.2337/dc17-1740

308. Saremi A, Howell S, Schwengen DC, Bahn G, Beisswenger PJ, Reaven PD. Advanced glycation end products, oxidation products, and the extent of atherosclerosis during the VA diabetes trial and follow-up study. *Diabetes Care*. (2017) 40:591-8. doi: 10.2337/dcd16-1875

309. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. *Cardiovasc Diabetol*. (2002) 1:1. doi: 10.1186/1475-2840-1-1

310. Botham KM, Wheeler-Jones CP. Postprandial lipoproteins and the molecular regulation of vascular homeostasis. *Prog Lipid Res*. (2013) 52:446-64. doi: 10.1016/j.plipres.2013.06.001

311. Ginsberg HN, Packard CJ, Chapman MJ, Boren J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. *Eur Heart J*. (2021) 42:4791-806. doi: 10.1093/eurheartj/ehab551

312. Packard CJ, Boren J, Taskinen MR. Causes and consequences of hypertriglyceridermia. *Front Endocrinol*. (2020) 11:252. doi: 10.3389/fendo.2020.00252

313. Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. *Endo Rev*. (2019) 40:537-57. doi: 10.1210/er.2018-00184

314. Wadström BN, Wulff AB, Pedersen KM, Jensen GB, Nordestgaard BG. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study. *Eur Heart J*. (2021). doi: 10.1093/eurheartj/ehab705. [Epub ahead of print].

315. Zhao Y, Liu L, Yang S, Liu G, Pan L, Gu C, et al. Mechanisms of atherosclerosis induced by postprandial lipemia. *Front Cardiovasc Med*. (2021) 8:636947. doi: 10.3389/fcmv.2021.636947

316. Pentikainen MO. Lipoprotein lipase in the arterial wall: linking LDL to the arterial extracellular matrix and much more. (2002) 22:211-7. doi: 10.1161/hq1012.101551

317. Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. *Vasc Health Risk Manag*. (2016) 12:171-83. doi: 10.2147/VHRM.S14369

318. Miname MH, Rocha VZ, Santos RD. The role of RNA-targeted therapeutics to reduce ASCVD risk: what have we learned recently? *Curr Atheroscler Rep*. (2021) 23:40. doi: 10.1007/s11883-021-00936-1

319. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*. (2018) 380:11-22. doi: 10.1056/NEJMoa1812792

320. Strandberg TE, Libby P, Kovanen PT. A tale of two therapies lipid-lowering vs. anti-inflammatory therapy: a false dichotomy? *Eur Heart J Cardiovasc Pharmacother*. (2021) 7:238-41. doi: 10.1016/j.ehjcvp/pvaa131

321. Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy. *Circulation*. (2018) 138:141-9. doi: 10.1161/CIRCULATIONAHA.118.034645

322. Randolph GJ. Tissue macrophages break dogma. *Nat Rev Immunol*. (2021) 21:625. doi: 10.1038/s41577-021-00628-0

323. Hettwer J, Hinterdober J, Mirtisch B, Deutsch MA, Li X, Maurersberger C, et al. Interleukin-1β suppression dampens inflammatory leukocyte production and uptake in atherosclerosis. *Cardiovasc Res*. (2021). doi: 10.1093/cvr/cvab337. [Epub ahead of print].

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Lorey, Öörni and Kovanen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.